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ABSTRACT 
 
Ischemic events associated with coronary heart diseases (CHD) are the leading cause of 
death worldwide for both genders. They are directly associated with restricted blood flow caused 
by accumulation of atherosclerotic plaque in vessel’s lumen. Percutaneous coronary intervention 
(PCI), including stent deployment, is currently considered as the dominant procedure for 
mechanically recovering myocardial perfusion to avoid lethal ischemic events. As vascular 
prosthesis, coronary stents suffer from two major and common complications; thrombosis and 
restenosis. Thrombosis is linked with insufficient migration of endothelial cells (EC) and 
proliferation at site of tissue injury. Restenosis is caused by unwanted proliferation of underlying 
vascular smooth muscle cells (VSMC). With drug eluting stents (DES) as a strategy to mitigate 
aforementioned complications, it only results in reducing VSMC proliferation. However, it 
directly causes poor endothlialization through undifferentiated inhibition of endothelial cells as 
well. This can result in high risk of late thrombosis, leading to death. 
Different strategies are being investigated to reach optimum duration and conditions for 
endothelium healing as a critical aspect of enhancement for drug eluting stents. In this thesis, a 
nanoarchitectured system is proposed as surface enhancement for drug eluting stents. Highly 
oriented nanotubes were vertically grown on the surface of a biocompatible Ti-based alloys, as 
potential material for self-expandable stents. The fabricated nanoarchitectured system is self-
grown from the potential stent substrate. This material is also proposed to enhance endothelial 
proliferation while acting as drug reservoir to hinder VSMC proliferation.    
Two morphologies were prepared to investigate the effect of structure homogeneity on 
the intended application. They were characterized for morphological investigation using Field-
emission scanning electron microscope (FESEM), X-ray diffraction (XRD), Raman 
spectroscopy, Energy dispersive X-ray spectroscopy (EDX) and X-ray photoelectron 
spectroscopy (XPS). Nanoindentation technique was used to study the mechanical properties of 
the fabricated material. Cytotoxicity and proliferation studies were done and compared for the 
two fabricated nanoarchitectures versus smooth untextured samples using in-vitro cultured 
endothelial cells. Finally, drug loading capacity was investigated practically and supported by 
computational study of release profile using COMSOL® Multiphysics software.  
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Chapter 1: Introduction and Scientific Background 
 
1.1. Coronary Heart Disease (CHD) 
 
 
Coronary heart disease (CHD) is described as the leading cause of death worldwide for both 
genders, especially in high and middle-income countries. It is responsible for 30% of deaths 
annually around the world and the death of almost 700,000 patients in the United States of 
America alone every year 1–3. It has been intrinsically associated with atherosclerosis since the 
beginning of the 20th century 1. Atherosclerosis is a degenerative disease that can begin as early 
as adolescence or childhood. It progresses silently until adulthood, when it can be manifested 
into clinical CHD that may end with death 4. Pathologically, atherosclerosis is characterized by 
the formation of localized plaques within arterial walls that hinder normal blood flow 5.  
 
As shown in Figure 1.1, atherosclerosis starts with the accumulation of fatty streaks, 
cholesterol deposits and its esters in arterial intima. Later, larger lipid deposits and cellular waste 
are accumulated and covered by a thick intima of connective tissue and smooth muscles, 
resulting in a fibrous plaque. That fibrous plaque can either stay stable and get calcified or can 
erode exposing the inner core to flowing blood, which in turn may accumulate into occlusive 
thrombus 4. When atherosclerotic plaques are localized in one or more of coronary arteries – 
known as coronary artery disease (CAD) – they prevent sufficient flow of oxygenated blood to 
the heart muscles. This results in an ischemic state at the heart muscle causing symptomatic 
events that range from angina pectoris to myocardial infarction and sudden death 6, see Figure 
1.2. 
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   Figure 1.1: Schematic representation of atherosclerosis timeline pathologically 7 
 
 
The clear-cut cause of atherosclerosis is not well-identified up till now. However, several risk 
factors were highlighted to significantly contribute in disease progression; such as hypertension, 
diabetes mellitus, smoking and most importantly uncontrolled blood lipid profile 1. Further 
identification of cholesterol role was revealed when high blood levels of low-density lipoprotein 
(LDL) cholesterol accompanied higher rates of CHD incidence, while high blood levels of high-
density lipoprotein (HDL) cholesterol were associated with lower rates of CHD incidence. This 
was further confirmed via controlled clinical trials conducted to clear out controversy about lipid 
hypothesis 4.  
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Figure 1.2: (A) death of part of heart muscle due to insufficient blood supply (B) Cross section 
of coronary artery with plaque built up and blood clot 8. 
 
 
 
1.2. Coronary Artery Stenting (CAS) 
 
1.2.1. Percutaneous Transluminal Coronary Angioplasty (PTCA) 
 
A number of practices is well-established for the treatment of atherosclerosis in order to 
restore coronary blood flow 9.  For long time, coronary artery bypass graft (CABG) remained the 
gold standard practice for coronary artery disease treatment. CABG, however, involves an 
invasive intervention to bypass blocked artery using a graft harvested from other body parts. This 
is accompanied by either during or post-surgery morbidity and mortality risks. In 1977, the first 
percutaneous transluminal coronary angioplasty (PTCA) was performed to replace CABG as a 
minimally invasive technique that spare CAD patients post-surgical risks and complications 1. 
PTCA involves the insertion of a balloon-tipped catheter through a small incision at a major limb 
artery. The catheter is guided over a thin radio-opaque wire that allows the procedure to be 
visible under the fluoroscope x-ray imaging. Contrast agents are injected in the circulation 
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concurrently to locate the site of the blockage. Upon reaching the site of occlusion, the balloon is 
then inflated to cause plaque compression and/or destruction, dilatation of arterial stenosis and 
allows the blood flow restoration, then the balloon is removed 10, 11, see Figure 1.3. 
 
 
 
 
Figure 1.3: Description of PTCA from site of catheter insertion till (A) reaching diseased site, (B) 
Balloon inflation and (C) Blood flow recovery after balloon removal 12. 
 
 
 
The success of the previously described plain balloon angioplasty was, however, threatened 
by the risk of re-narrowing and possible need of emergency CABG. It was noticed that post-
procedural arterial response involved 5% risk of acute restenosis during the first 24 hours, or 20-
50% risk of late occlusion during the first six months. After investigation, this was attributed to 
tissue trauma during the mechanical restoration of blood flow and morphological alterations that 
affected the arterial wall. Consequently, arterial smooth muscles undergo elastic recoiling and 
negative remodeling takes place through a decrease in external diameter of the artery during 
healing. To eliminate such serious complications, bare-metal stents (BMS) were introduced to 
act as a residing scaffold to prevent arterial collapse incurred by plain balloon angioplasty 10,13.  
Stents are expandable wire-meshes in the form of tubes, which come in a wide range of designs 
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and materials, based on implantation procedure and patient's case. As shown in Figure 1.4, they 
are used as a supporting structure to prevent the artery from collapsing after balloon angioplasty 
to maintain blood flow 10,14.  
 
 
 
 
 
Figure 1.4: Stent delivery mounted on a balloon-tipped catheter during PTCA. (A) Stent crimped 
on deflated balloon, (B) stent expands with balloon inflation, and (C) balloon left in place after balloon 
removal 15. 
 
 
 
 
1.2.2. Drug Eluting Stents (DES) 
 
After the introduction of BMS to the angioplasty procedure, patients' follow ups and clinical 
studies showed that restenosis rates were only improved to 20% - 30% 16, while in patients with 
complex lesions, such rates can go up to as high as 60% 11.  Further investigation attributed the 
renarrowing at the treated location to what is known as neointimal hyperplasia. Hardly 
controllable intima reaction and hyper proliferation of the vascular-lining tissue led to in-stent 
occlusion, which required medical re-intervention 10,14. Clinical studies that investigated the 
potential of avoiding this complication using systematic drugs such as antithrombotics and 
glucocorticoids have generally failed 17. In a more successful attempt to reduce the number of 
patients that suffer from recurrent stenosis and clinical CHD, a therapeutic agent was introduced 
locally on the stents platform to combat hyperplasia, offering what is known as drug eluting 
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stents (DES) 1. DES successfully emerged to revolutionize the field of intervention cardiology 
with decreased restenosis rates below 10% 18. They became more preferred choice although they 
were only introduced in 2003. By 2006, 8 out of 10 deployed coronary stents were DES 19, at an 
annual cost between 4 to 5 billion USD 20.  
 
The emergence and development of DES is considered a successful example of 
multidisciplinary research that offers a life-saving solution to one of the most prevalent death-
causing problems worldwide. It combines the understanding of the restenosis biology, 
pharmacology and appropriate drug selection, drug release and delivery strategies as well as 
material in-depth studies 22, 23.  The drug is meant to inhibit neointimal hyperplasia by 
suppressing one or more processes involved in the biology of the restenosis. Accordingly, 
therapeutic modalities of the loaded drug can be classified mainly into antiproliferative, anti-
inflammatory, migration inhibitors and immunosuppressive as well as prohealing and anti-
thrombotic agents 24, 21. These types of DES and most famous examples from each class are 
summarized in Table 1.1.    
 
Clinical evaluations have so far overwhelmingly showed strong evidence of DES superiority 
over BMS in reduction of in-stent restenosis rates. However, cases of serious clinical events have 
raised concerns over DES long time safety and efficiency 6. In particular risks of late and very 
late stent thrombosis are considered 25. Several proposals have been offered to explain why such 
technical marvels would turn to be thrombogenic. Some of the most supported reasons are; 1- 
delayed endothelialization due to locally delivered cytotoxic or cytostatic drugs or other 
pathological risk factors, 2- inherent thrombogenicity of the stent as a foreign body to blood 
circulation, 3- hypersensitivity reactions related to the metallic material used for stent 
manufacturing or/and polymeric coatings used as drug carriers, 4- dual antiplatelet therapy 
(DAPT) early discontinuation, and 5- stent malapposition or incomplete apposition, related to 
technical deployment 26–29.   
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Table 1.1: Types of DES and most famous examples from each class 21. 
 
 
Anti-inflammatory 
Immunomodulators 
 
Anti-proliferative 
 
Migration inhibitors, 
ECM* modulators 
 
Promote healing and 
endothelialization 
 
Dexamethasone  
M-prednisolone 
Interferon γ-1b 
Leflunomide 
Sirolimus (and 
analogues) 
Tacrolimus 
Mycophenolic acid 
Mizoribine 
Statins  
Cyclosporine 
Tranilast 
Biorest 
Abciximab 
 
QP-2, Taxol 
Actinomycin 
Methotrexate 
Angiopeptin 
Vincristine 
Mitomycin 
Statins  
C-MYC antisense 
Sirolimus (and 
analogues) 
RestenASE 
2-chloro-
deoxyadenosine 
PCNA ribozyme 
Abciximab 
 
 
Batimastat 
Prolyl hydroxylase 
inhibitors 
Halofuginone 
C-proteinase 
inhibitors  
Probucol 
Abciximab 
 
BCP671  
VEGF 
Estradiols 
NO donors 
EPC antibodies 
Biorest 
Advanced coatings 
Carvedilol 
Abciximab 
*ECM: extracellular matrix, PCNA: proliferating cell nuclear antigen, VEGF: vascular endothelial 
growth factor, NO: nitric oxide, EPC: endothelial progenitor cell 
 
 
Accordingly, the Food and Drug Administration (FDA) has increased the recommended 
duration for systematic DAPT to double it into at least one year, to reduce the incidence of late 
stent thrombosis 30. Such increase has multiple side effects such as high risk of bleeding, 
complicated patient management after any surgical procedure and high costs. Therefore, current 
research is concerned with improving DES performance and long-term safety, using different 
approaches and multidisciplinary solutions that tackle any or all of the previously mentioned 
causes of thrombosis, while sparing the need of long-term DAPT 6, 25. 
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1.3. Material Perspective for Stent Substrate 
 
A wide range of different materials has been used in the manufacturing of stents. These 
materials need to fulfill a number of rigorous properties; mechanical, physical and chemical 
ones. According to procedure of implantation, long term application and safety, these properties 
are strongly studied and directly affect the choice of stent 14. An ideal stent has been described 
with many characteristics in plentiful reviews. They should generally possess (1) low profile, i.e. 
easily crimped on the balloon-tipped catheter for facile deliverability; (2) flexibility to travel 
through narrow vessel whenever needed; (3) satisfactory radio-opacity to be visible for the 
clinician during the procedure; (4) acceptable expandability ratio, i.e. as the balloon is inflated, 
the stent should be able to expand sufficiently and conform to the morphology of the vessel; (5) 
adequate radial strength supported by high tensile strength, i.e. stent should withstand imposed 
force by the arterial wall and avoid collapsing; (6) biocompatibility to avoid platelets adhesion 
and inflammatory reactions; (7) capacity to deliver drug locally to treated site; (8) compatibility 
with magnetic resonance imaging (MRI). In addition, an ideal stent material would have high 
elastic modulus to avoid recoiling, and low yield strength to expand during deployment at 
acceptable balloon exerted pressure 16,31. 
 
1.3.1. Permanent Stents 
 
Medical implants in general are not only made of metals, but also ceramics and polymers. 
However, ceramics and polymers lack few of the previously mentioned critical properties needed 
for ideal stents, especially mechanical properties. Hence, metals are the main materials used so 
far for the manufacturing of coronary stents. Combination of properties described above is 
substantially difficult to meet in a single material. Therefore well studied compromise is always 
essential to be found, and research is still intensively ongoing to tackle this issue 31.   
 
1.3.1.1 Balloon Expandable Stents 
 
The metals commonly used in the manufacturing of stents are 316 L stainless steel (SS), 
cobalt-chromium (Co-Cr) alloys, platinum (Pt) alloys and Nitinol (Ni-Ti), which will be 
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specifically described in a later section, under "self-expandable stents". Table 1.2 summarizes the 
main mechanical and physical properties of such materials. SS, Co-Cr and Ni-Ti alloys are 
widely used in different biomedical applications due to their high corrosion resistance, high 
elastic modulus and high ductility. Although other materials can show better corrosion resistance 
and biocompatibility such as titanium (Ti) alloys, currently used Ti-alloys in biomedical field, 
such as Ti-6Al-4V alloy, lack sufficient ductility, strength and density needed for coronary stents 
16,31. Further details are presented below describing 316L SS, Co-Cr alloy and Pt alloys as they 
are the three most commonly used materials in manufacturing stents currently available in the 
market and Ti alloys as they are crucial for the scope of this thesis.   
 
 
Table 1.2: Mechanical and physical properties for selected biomaterials, used for stent manufacturing 
16,31. 
 
 SS 316L Co-Cr (L605) Nitinol Pt-10Ir Ta Cp-Ti 
Density (g/cm3 ) 
Elastic Modulus 
(GPa) 
 UTS (MPa) 
Yield Strength 
(MPa) 
 Elongation (%) 
7.95 
193 
 
670 
366 
 
43 
9.1 
243 
 
1147 
629 
 
46 
6.45 
90 
 
1400 
195–690 
 
14 
21.55 
150 
 
340 
200 
 
25 
 
16.6 
185 
 
207 
138 
 
25 
 
4.5 
107 
 
760 
485 
 
30 
 
 
Stainless steel (SS) is iron-based alloy that can be prepared in different grades used for 
different applications, according to the desired properties. These grades are differentiated 
according to the type and percentage of added elements that comprises the alloy along with iron. 
These elements include Ni, Cr, Mo, Nb, Ti, and N, and they directly affect the alloy's strength, 
microstructure and corrosion resistance. Although SS does not corrode in oxygen containing 
environment. However, they may locally corrode in chloride containing media such as human 
fluids 16,31,32.  
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Austenitic 316L SS has sufficient mechanical properties making it well-suited for stent 
application and the main metal used for stent manufacturing for a long period of time, see Table 
1.2. The corrosion resistance of SS is increased by adding up to 3% Mo, and up to 15% Ni, while 
reducing carbon content below 0.030% 31,33. However, with such relatively high content of Ni as 
well as presence of Mo and Cr, these ions can be released to the surrounding tissues causing 
local immune response and allergic reactions, which would contribute significantly to in-stent 
restenosis. Also, carbon content can result in the formation of carbides at the grain boundaries 
reducing the corrosion resistance at those areas. Moreover, with more than 60% Fe content in SS 
it possesses ferromagnetic properties that would clinically interfere with MRI that the patient 
may need to undergo. While on the other hand, it has relatively low density that hinders 
sufficient visibility during PCTA procedure. Therefore, the use of SS is dependent on the use of 
coating material that would solve some of the challenges mentioned above, yet may not be able 
to solve others 34,35. 
 
Co- Cr alloys have been used broadly in biomedical applications for decades and have been 
replacing SS stents commercially in the past few years along with Pt-alloys. They have 
outperformed SS both during and post deployment 16,31. As seen in Table 1.2, they have higher 
density that makes them more radiopaque and facilitate guidance during angioplasty. They have 
high tensile strength, which allows for thinner struts for better deliverability and lower rates of 
stent fracture 36. They are also characterized by high elastic modulus limiting stent recoiling. 
Moreover, they demonstrate high corrosion and wear resistance, which reduce the risk of late 
complications 37,38. 
 
Pt alloys possess great potential in the field driven by their biocompatibility, anti- corrosion 
and improved radiopacity 31. For example Pt-Cr alloy showed enhanced endothelialization, high 
corrosion resistance and comparable mechanical properties to stainless steel due to its chromium 
content 39. While Pt-Ir (90% Pt – 10% Ir), for example, showed enhanced radiopacity, reduction 
in inflammatory reactions and incidence of thrombosis. However, they showed higher rate of 
recoiling and their mechanical properties are still under question 40.   
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Titanium (Ti) and its alloys have been widely used in biomedical field especially in dental 
and orthopedic applications. They show excellent biocompatibility and high corrosion resistance 
due to the oxide layer formed on their surface, which is highly stable. However, for coronary 
stent manufactory, Ti application has been limited to bio-inert coatings that showed significantly 
reduced thrombogenicity and intimal hyperplasia, such as Ti-nitride-oxide layer on Titan© stent 
(Hexacath, France) 16,31,41 
 
The reason why pure titanium or some of its common alloys are not used as stent material is 
due to its mechanical properties that does not match the requirement of ideal stent. It has high 
yield strength but relatively low tensile strength. Therefore, during deployment with balloon 
expansion, they will need to expand to stresses beyond their yield strength. Furthermore, with Ti-
alloy low tensile strength and low ductility, the stent will be easily prone to fracture. Using 
materials in the alloy that would reduce its yield strength might be a good strategy to make it 
mechanically acceptable, while keeping the original tensile strength. Some of the promising Ti-
alloys for making stents are Ti-based Tantalum (Ta) and Niobium (Ni) alloys, which showed 
outstanding haemocompatibility 42. Also, Ni-Ti alloys are extensively used in stents 
manufacturing at almost equal percentages of both elements. This will be briefly discussed below 
under “self-expandable stents” section 43. 
   
 1.3.1.2. Self-expandable Stents  
 
One of the stents classifications depends on method of deployment into the vessel during the 
PCTA. Accordingly, they are classified into balloon expandable stent (BX) – as described 
previously and shown in Figure 1.4 – and self-expandable stent (SX), see Figure 1.5. BX is 
manufactured crimped and mounted on a balloon that inflates at the required site expanding the 
stent along with the balloon inflation. SX is manufactured at or slightly above vessel diameter 
then constrained in the crimped state within a sheath till it reaches site of delivery 44.  Therefore, 
materials used for BX should have the ability to undergo plastic deformation during deployment, 
and then preserve required size once positioned. However, materials for SX should have enough 
elasticity to be compressed while delivered, and then expand in place 14,16. And it is fair to say 
that balloon expandable stents resist balloon expansion, whereas self-expandable ones assist it.  
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Figure 1.5: Self-expandable stent; introduced crimp within a sheath. After reaching delivery site, 
sheath is removed and the stent expand to its original shape 45. 
 
 
BX can suffer from mechanical failure and collapse if subjected to external pressure that 
exceeded its critical value. While on the other side, SX will not suffer from same strength 
limitation by virtue of its elastic properties that permit its radial recovery. Also, SX was found to 
be superior to BX in maintaining vessel radial compliance after stenting, which is a measure of 
yielding to pressure without disruption. Therefore, if a healthy vessel would have 6%/100 mmHg 
compliance normally, this number would be 3-4%/100 mmHg compared to less than 1%/100 
mmHg compliance after SX and BX stenting, respectively. Furthermore, bending compliance is 
higher for SX, which gives an advantage at both delivery and deployment. This leaves the stent 
more conformable and adaptable to vessel shape avoiding high stresses at the end of the stent, 
which may contribute to intimal hyperplasia. However, on the other hand, concerns regarding SX 
are still raised due to risk of acute recoil with calcified lesions, recovery from buckling with 
large stents and placement technical challenges 44,46.  
 
One of the most widely used materials for self-expandable stent manufacturing is Nitinol 
(Ni-Ti alloy). It consists of approximately equal atomic amounts of both nickel and titanium; 
49.5-57.5% wt% Ni and the rest is Ti 16,31. They have unique mechanical properties that highly 
favor their use in SX, such as shape memory and superelasticity. Shape memory effect allows the 
material to return from its deformed shape into its original one by heating. Superelasticity allows 
apparent plastic deformation to return to original shape when load is released. Nitinol SX are 
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manufactured at a size slightly higher than vessel diameter. They deform plastically under room 
temperature and are crimped onto delivery system. Under the effect of body temperature, they 
expand to regain their original shape conforming to the vessel diameter. As shown in Figure 1.6, 
Nitinol has similar behavior to natural body structural materials such as bones, hair and tendons. 
These materials can be deformed elastically up to 10% strain. Such strain can be recovered at 
lower stresses after the release of the stress, and loading/unloading curves are characterized by 
the so called hysteresis 31,43.  
 
 
 
Figure 1.6: Mechanical compatibility of Nitinol with body structural material 43. 
 
 
1.3.2. Biodegradable Stents 
 
Basically, stents are supposed to function as a mechanical support for the blood vessel and 
prevent acute recoiling until endothelial tissue is regenerated and regain its integrity. Hence, the 
stent role is temporary and long term existence can be unnecessary. The concept of 
biodegradable stent became, therefore, very appealing and drew the attention of research 
community as well as stents industry. It spares patient from long term complications such as 
risks of in-stent restenosis, late stent thrombosis, persistent vessel stiffness and incompatibility 
with future interventions 47.  
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Ideal biodegradable stent material should be able to compromise mechanical integrity versus 
degradation on implantation site. As shown in Figure 1.7, degradation would begin theoretically 
at low rate when mechanical integrity is still needed and maintained. After a period of 6-12 
months, vessel remodeling is believed to be completed, hence higher rate of degradation 
thereafter is acceptable. Two classes of materials are used for biodegradable stents; metallic 
materials such as Mg- or Fe- based alloys, and polymeric materials such as lactic, glycolic and 
caprolactone families. Although biodegradable stents witnessed high research and market 
interest, many concerns are yet to be evaluated and answered before replacing current 
technology. These concerns include safety issues regarding degradation products and 
degradation mechanism 48, as well as practical implication of mechanical compromise over time 
that was discussed above.   
 
 
 
 
Figure 1.7: Theoretical material biodegradation over time, versus its mechanical integrity 47.  
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1.4. Surface Treatment 
1.4.1. Polymeric Coating 
 
      Coatings have been initially used to enhance the biocompatibility of stent materials within 
vascular environment. Later, they were used as vehicle for drug loading and a platform to offer 
advanced solution for better endothelialization. Currently, the most widely used coating 
materials for different types of stents are polymeric coatings 16. Permanent polymer coatings, 
which have been used initially for DES,  showed impaired vascular healing and were found to be 
responsible for inflammatory responses due to permanent contact with the arterial wall 49. It 
carried the blame on late stent thrombosis along with other patient and lesion related factors 50. 
 
Biodegradable polymers have, therefore, appeared to be an appealing alternative to durable 
polymers as stent coating. They are more likely to avoid chronic inflammatory response and long 
term complications, as they degrade over certain amount of time and their degradation product 
theoretically get washed out from human body. Materials used for such coatings may include 
poly lactic acid (PLA), poly lactic-co-glycolic acid (PLGA) and poly caprolactone (PCL) 48.  
Drug release is controlled with these materials based on their degradation profile over time. 
Challenges are though still remaining for advancement in polymeric coatings. These challenges 
include for example; establishing optimal formulation and degradation time, pharmacokinetics of 
drug release during degradation and fate of degradation by-products.  50.     
 
1.4.2. Nanoporous Surface 
 
Reference to polymer-related concerns described above, porous platforms offer a promising 
step forward in the advancement of DES as polymer-free surfaces. They avoid polymer long 
term inflammatory responses, improve healing process, improve surface integrity by avoiding 
polymer peeling and can still act as drug reservoirs. Moreover, they were found to promote rapid 
endothelialization. This was first investigated by creating micropores on the vascular graft wall, 
as shown in Figure 1.8, using different techniques 51–53.  
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 Figure 1.8: VESTAsync DES system. Top images picturing stent struts at different magnification 
and bottom ones are SEM (Scanning Electron Microscopy) images of their microporous Hap (Hydroxy 
apatite coating 51. 
 
It was found that increased pore density resulted in an enhanced endothelialization and 
formed thinner intima 54. Also to better control sustainable release of the drug from the porous 
reservoir and avoid burst effect, smaller pores may be required to retard quick release 16. Hence, 
the use of nanotechnology advances in stents surface treatment is investigated in attempt to fulfill 
such favored requirements. It involves the design and development of structures and materials 
with at least one dimension ranging in size between 1- and 100- nanometer. Such size allows the 
structure to manipulate matter at its atomic scale, offering exceptional opportunities at biological 
interfaces. Using nanoporous assemblies on surface of graft material not only act as drug 
reservoir but also play a critical role in fast healing 55.  
 
The concept certainly have merits and their positive influences on tissue regeneration have 
been already explored for different medical devices, however, research is still extensively 
required to study the potential use of this kind of surface treatment. Concerns that still need 
answers include; thrombogenicity of such rough surfaces, mechanical performance during and 
after deployment, drug-release profiles of different morphology and preparation techniques for 
controlled morphologies on the surface of different biocompatible materials 38.  
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1.4.3. Other Surface Treatment 
 
A wide range of other coating types has been explored for stent material for different 
functional advantages 38. For example, 1- anti-corrosive metal oxides such as titanium dioxide, 
significantly decrease metal ion release from core material enhancing biocompatibility; 2- silicon 
carbides that allow electron transfer between the metallic surface of the stent and  blood proteins 
to reduce in stent fibrinogen deposition and stent thrombosis; 3- carbon coating for lower rates of 
metal ion release and platelet aggregation; 4- titanium- nitride-oxide coating as barrier against 
metal ion and to regulate endothelialization; 5- endothelial cells seeding on stent surface to 
promote endothelialization and fast healing; 6- biotechnology advances that use anti-endothelial 
progenitor cells (anti-EPC) in contact with blood flow to capture EPCs, which are seed for 
endothelial tissue growth, promoting controlled tissue growth (see Figure 1.9). Some of those 
previously mentioned approaches are proven clinically insignificant or even failed avoiding late 
complications, while others are being currently adopted commercially and considered state-of-
the art material treatments, which are beyond the scope of this thesis and discussed efficiently 
elsewhere 16,25,29,31,38,50.   
 
 
 
Figure 1.9: EPCs capturing technology by Genous ® stent for enhanced endothelialization 56. 
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Thesis Scope and objectives 
 
Reference to the challenges facing Drug Eluting Stents (DES) described earlier in this 
chapter, we can summarize saying that ideal surface properties for DES should offer the 
following: 
(1) Material biocompatibility. 
(2) Pro-healing bioactivity to avoid neointimal hyperplasia, while promoting control 
endothelial healing. 
(3) Capacity for drug loading. 
(4) Mechanical integrity. 
 
With the aim to fulfill these objectives, nanoarchitectures were investigated in this thesis as 
surface treatment for potential biocompatible DES material. As will be elaborated in chapter 2, 
nanoporous structures and nanotubes arrays were found to be very promising for enhancing 
tissue regeneration and as drug loading vehicle to be used for wide range of biomedical 
applications. For extending and supporting these efforts to be used for intravascular stents the 
following work will be covered in this thesis. 
 
(1) Fabrication of nanoarchitectures on the following materials, a) pure titanium, b) Ti-45Ni 
alloy and c) Ti-17Nb-6Ta which possesses mechanical properties matching with those required 
for self-expandable stents.  
(2) Studying different properties for fabricated nanoarchitectures through various 
characterization techniques. Characterization would include; morphological, mechanical, 
compositional and structural. 
(3) Investigating the effect of different nanoarchitectures as surface treatment on biological 
response. And comparing their bioactivity versus smooth surface of the same material. This will 
be assessed through in-vitro studies using vascular endothelial cells.    
(4) Studying the drug loading capacity of different morphologies. 
(5) Calculating drug release profile for the most promising nanoarchitecture using 
computational simulation.  
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Chapter 2: Literature Review 
 
2.1. Formation of Nano-tubular Anodic Oxide Layer on Ti and Ti-alloys 
 
There has been an amplified interest recently in exploring nanoscale surface topography for 
implantable devices such as dental and orthopedic prosthetics, grafting materials and 
intravascular stents – as will be described below 57. Titanium and titanium alloys possess 
superior properties relative to many other materials in terms of  biocompatibility, corrosion 
resistance, specific densities as well as mechanical properties that are tuned with alloy material 
and according to the intended application 57,58. Consequently, nanotubular oxide structures 
formed on the surface of titanium and its alloys have been extensively investigated for enhancing 
the performance of biomedical implants, especially TiO2 nanotubes 
57- 66. 
 
Different techniques have been used for the fabrication of these structures such as sol-gel, 
atomic layer deposition, hydro/solvothermal methods and micelle templates 59–66. However, 
among these methods, one technique showed superior control on the dimensions and 
morphology of the nanostructure, which is electrochemical anodization in fluoride-containing 
electrolytes. It is also relatively simple, scalable, cost-effective and applicable for complex-
shaped base material 67. Early report of achieving self-organized TiO2 nanostructure using 
anodization was by Zwilling, et al in 1999 who produced nanoporous assembly of TiO2 on Ti-
based alloy in acidic medium 68.  In 2001, Gong, et al first reported the formation of highly 
ordered TiO2 nanotube array by anodizing titanium in dilute HF electolyte 
69. Efforts to optimize 
these nanotube arrays have been ongoing for more than a decade now to be used for a wide range 
of promising applications. It was found that anodization process, and accordingly the final 
surface nanomorphology and composition, are drastically affected by anodization conditions, 
such as, applied potential, time, pH and fluoride species concentration 67. Some of these efforts 
are summarized in Table 2.1 below. 
 
Since the work of Grimes, et al in 2001, the development of TiO2 is grouped into three 
generations reference to the nature of the electrolyte used. First generation TiO2 nanotubes were 
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achieved by aqueous HF based electrolytes, see Figure 1.2. They are characterized by relatively 
short length with maximum of 500 nm 69,70.  
 
Table 2.1: Summary of titania nanotubes properties under different anodization conditions 71. 
 
Length
/µm 
Wall 
Thickness/ 
nm 
Diameter
/nm 
Voltage/
V 
Time/
h 
Main 
solvent 
Conditions Ref. 
 
0.12  
1.76 
0.36  
0.50 
3.5 
18 
0.5 
1.9–5.7 
6 
 
10 
15 
7-35 
134 
45 
93 
220 
360 
380 
538 
1000 
 
 
9 
 
17 
˂10 
 
 
15 
8 
20 
 
˂20 
 
15 
25 
15 
- 
50 
20 
 
22 
65 
46 
150 
 
 
100 
 30 
110 
 
15-110 
 
130 
160 
120 
200 
110 
120 
 
10 
20 
12 
5–15  
60 
20–60 
20 
20 
 
 
20-50 
50 
60 
60 
40 
60 
50 
60 
 
6 
10 
 
4 
 
 
2 
16–70  
 
 
1 
12 
 
17 
69 
70 
17 
96 
168 
168 
216 
 
H2O 
EG* 
H2O 
Glycerol  
EG 
EG 
H2O 
GL 
H2O 
 
EG 
EG 
EG 
EG 
DMSO** 
DMSO 
Formamide 
EG 
 
0.5% HF + acetic acid (7 : 1) 
0.2M NH4F+0.1M H3PO4+2% H2O 
0.5% HF + acetic acid (7 : 1)  
0.5  wt% NH4F 
0.25 wt% NH4F  
0.25 wt% NH4F 
0.5 wt% NH4F 
0.5 wt% NH4F  
0.1 M KF + 1 M NaHSO4 0.2 M 
trisodium citrate sodium hydroxide 
0.25 wt% NH4F 10 wt% H2O 
0.25 wt% NH4F 
0.25 wt% NH4F 2 vol.% H2O 
0.25 wt% NH4F 
2% HF 
2% HF 
NH4For HF, 2% H2O 
0.3 wt% NH4F, 2% H2O 
0.3 wt% NH4F 
0.4 wt% NH4F, 2.5% H2O 
0.3 wt% NH4F, 3.5% H2O 
 
72 
 73 
74 
75 
 
 
76 
77 
78 
 
79 
80 
81 
82 
 
 
83 
84 
  *EG: Ethylene Glycol 
** DMSO: Dimethyl Sulfoxide 
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For the second generation, nanotube length was increased up to 7µm. This was achieved by 
controlling the electrolyte pH and accordingly the chemical dissolution of TiO2 during the 
process of anodization. In 2004, Grimes, et al used electrolyte solution containing sodium 
fluoride (NaF) or potassium fluoride (KF) to produce nanotube arrays that would belong to the 
second generation. They adjusted the pH to 4.5 using sulfuric acid, sodium hydrogen sulfate, 
sodium hydroxide and/or citric acid. They were able to produce nanotubes up to 4.4 µm, see 
Figure 2.1 85. One year later, Grimes, et al were able to again produce longer nanotubes – relative 
to first generation – using different electrolytes and conditions. They used 1:1 flourinated 
dimethyl sulfoxide (DMSO) and ethanol to produce nanotube arrays of 2.3 µm 86.  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: SEM images for TiO2 nanotubes arrays for (a) first generation 69, (b) second generation 85, (c) 
third generation 82     
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Third generation of TiO2 nanotubes array was achieved in later work by processing in non-
aqueous, polar organic electrolytes such as ethylene glycol and formamide, reaching tubular 
length of up to 1000 µm. In 2006, Grimes, et al succeeded to produce nanotube array up to 134 
µm in length, see Figure 2.1. They used a variety of polar organic electrolytes as mentioned 
earlier, along with fluoride ion donor as KF, NaF or HF. They reported that the key to successful 
fabrication of long arrays is in keeping water content below 5% 82. This was followed by several 
successful attempts to produce arrays of length above 100 µm. In 2007, they reported for the first 
time self-aligned nanotube arrays of titania about 1000 µm in length and 10 000 aspect ratio, 
using NH4F and ethylene glycol-based electrolytes 
84, see Figure 2.2. Finally, fourth generation 
is suggested to be one with fluoride-free electrolyte chemistries 87. 
 
 
 
Figure 2.2: SEM images of the first reported nanotube arrays of length 1000 µm (third generation) 
using organic electrolyte. (a) top view, (b) bottom/barrier view, (c), (d) cross-sectional view 84.  
 
25 
 
In addition to morphological characteristics of the titania nanotubes arrays, their properties 
depend on the crystallinity and isomorph type. This directly affects its utility for different 
applications, including efficiency at biological interfaces in biomedical applications. As-
fabricated nanotubes are amorphous. Upon annealing in oxygen at elevated temperatures, tube 
walls are converted into anatase and rutile phases, respectively. As the anodization voltage 
increased, amount of anatase formation becomes higher 88–92. The rutile phase initially starts at 
the interface between the nanotube arrays and the support. At elevated temperatures (above 550 
oC), rutile crystallites merges with the nanotubes and transforms into compact rutile layer as 
temperature reaches 800 oC 93.      
 
In-application efficiency also relies on the integrity of the titania nanotubes layer at the 
functioning site. Unfortunately, weak adhesion has been reported between the nanotubes layer 
and the metallic substrate, leaving them prone to be peeled of easily 94, 95. Therefore, several 
attempts have been conducted to understand the main cause of such phenomenon and offering 
practical solution to it. Schmidt-Stein, et al thermally treated TiO2 in acetylene atmosphere to 
transfer it to its semi-metallic form (TiOxCy). They explained that incorporating carbon to its 
microstructure enhanced the layer's mechanical strength 96. Xiong, et al annealed TiO2 nanotubes 
for different time durations and reported that adherence improved actually with annealing time 
97. Recently in 2014, Yu, et al introduced 200 nm thick oxide layer near the nanotube bottom by 
adding fluoride-free anodization step prior to the main anodization process, see Figure 2.3. They 
introduced this approach to reduce the fluoride rich TiO2 layer found at the interface with 
metallic substrate that is believed to be responsible for poor layer adhesion. They reported that 
this approach, increased adhesion strength almost three folds 98. 
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Figure 2.3: SEM images of top view on the left and side view on the right of titania nanotube arrays 
(c,d) with and (a,b) without additional oxide layer by fluoride free anodization 98. 
 
 
The same principle of using electrochemical anodization technique was extended to titanium 
alloys for producing oxide layer of nano-scaled topographies 67. In fluoride-containing 
electrolytes, fabrication of nanostructured oxide layer for titanium alloys using anodization 
technique was tailored for wide range of alloys with endless virtual possibilities, to be used in 
different applications; some of which are summarized in Table 2.2 below. 
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Table 2.2: Summary of TiO2 nanotubes’ properties made from alloys under different anodization 
conditions 71. 
 
Alloy Length
/ µm 
Diamete
r/nm 
Vol/V Time/ 
min 
Main 
solvent 
Conditions Ref. 
 
Ti45Nb (45 wt% Nb) 
 
TiMo (7 wt% Mo) 
Ti–0.2 wt% V 
Ti–3 wt% V  
Ti–18 wt% V 
TiNb (0.1 wt% Nb) 
Ti–0.2 wt% W  
Ti–9 wt% W 
TiN 
 
Ti -45wt% Nb 
Ti- 35wt% Ta 
Ti- 50wt% Zr 
 
2.9 
6.3 
4-16 
1 
 
 
1-15 
1.1-1.2 
 
650 
 
50 
50 
30 
 
60 
 
15-45 
120-130 
 
 
50-65 
85-95 
 
20-80 
 
20-50 
30-90 
10-15 
 
20 
 
20-60 
60 
 
 
50 
120 
 
20 
 
40 
 
 
120 
20h 
 
15-20 
 
 
5-120 
10 
12 
120 
 
˂1 
 
water 
 
EG 
EG 
 
 
EG 
EG 
 
Glycerol + 
water 
Cl- 
perchlorate 
 
1 M NaH2PO4, 0.5 wt% HF 
 
0.05 M HF 
0.2 M HF 
 
 
0.1 M NH4F+ 1 M H2O 
0.2 M HF 
 
0.27 M NH4F 
 
0.05 M NaClO4 +0.05 M 
NaCl in 50:50 vol% of 
H2O:C2H5OH 
 
99 
 
100 
101 
 
 
102 
103 
 
104 
 
105 
 
 
Generally, the composition of the oxide layer and the ratio of materials, directly reflect the 
properties of the alloy. This was demonstrated by Kamkin, et al for anodic oxide films on 
titanium-aluminum alloys. They showed that the mainly amorphous oxide film consists of TiO2 
and Al2O3  mixture with ratios perfectly consistent with the alloy matrix 
106. This phenomenon 
was likewise observed for TiTa alloy by Jha, et al. However, they also reported another behavior 
observed for other alloys, such as TiNb and TiZr. These alloys showed mixed oxides in the 
anodized layer along with oxides of individual components, as shown in Figure 2.4 105. On the 
other side, full conversion of the anodized surface into mixed oxide was reported by Yasuda, et 
al for TiZr alloy, as shown in Figure 2.5 107.   
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Figure 2.4: XRD spectra of oxide nanotubes for different titanium alloys, before and after annealing. 
Oxides from (a) TiNb alloy, (b) TiZr alloy, and (c) TiTa alloy 105. 
 
 
Figure 2.5: XPS spectra of (a) O 1s, (b) Ti 2pa (c) Zr 3d, for the as-grown and annealed nanotubes of TiZr 
alloy 107. 
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2.2. Biological Response of Nanotopography on Surface of Titanium and 
Titanium Alloy 
  
The response of biomaterials entirely depends on biocompatibility and surface properties. 
Hence, beside the choice of substrate material, paying attention to surface treatment is crucial for 
all biomedical applications  108. As mentioned earlier, nano-architectures have been extensity 
studied as surface treatment for biomaterials. They are considered as biomimetic interfaces that 
accordingly provide solutions to few biocompatibility challenges and enhance tissue regeneration 
57. Experimental evidences have recently been accumulated to show the importance of surface 
topography of biomaterials at the nanoscale and its effect on biological microenvironment 109.  
 
For orthopedic implants, this has been studied for years now and positive effects of 
nanostructures on tissue adhesion and regeneration are well-established. This motivated the 
exploration of those structures for other applications in contact with human tissue or blood 
components such as intravascular stents. Minagar, et al reported that bone cells response to 
implant material is affected by topography, mechanics, physicochemical and electronics of 
implant surface 110. Hence, as suggested by Webster, et al the bioactivity of the implants can be 
considerably improved using nanostructured oxide materials 111. Hamlekhan, et al further 
elaborated that anodized nanotubular surfaces were found to promote osteoblast cell adhesion, 
hydroxyapatite growth, improved integration and proliferation. This is attributed to increased 
surface area offering more area for cell interaction, protein adsorption, surface energy as well as 
increased hydrophilicity 112.  
 
Oh, et al studied MC3T3-E1 cell growth and proliferation on TiO2 nanotubes array versus 
pure Ti. Cell growth on TiO2 nanotubes substrates was found to be much faster. This was 
justified by the surface area presented by the nanotubes pores and in-between gaps that offered 
ions, proteins and nutrients continuous supply 113.  Effect of pore diameter on osseointegration 
was an area of investigation for many research groups. Wang, et al studied diameter effect on 
mechanism of biological attachment of implants to surrounding tissue. They used 30, 70 and 100 
nm nanotubes structures with in-vivo implants and observed histological features of bone 
surrounding the implant. Best results were reported for 70 nm diameter nanotubes 114. Kang, et al 
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also studied osseointegration over the same range of diameters. Highest values were also 
reported for 70 nm after 4 weeks. However, higher values with 30 nm nanotubes structure were 
observed after 12 weeks 115. 
 
Almost 2 decades ago, Steele, et al have reported that protein adsorption is higher on 
hydrophilic surfaces than hydrophobic ones 116, which presents a critical step in cell adhesion 
and implant bioactivity. Giordano, et al demonstrated that TiO2 nanotube formation on the 
substrate surface decreased water contact angle (WCA) 117. Therefore, in order to enhance tissue 
integration, adhesion and proliferation efforts have been accordingly exerted to increase 
hydrophilicity of the implant surface. Terriza, et al induced superhydrophilicty on titania layer by 
light using UV illumination. They reported highly enhanced cell attachment on immediately 
illuminated titania surface 118. Chang, et al studied titania nanotube contact angle at different 
anodization time (5, 20, 40, 60, 90 min and 24 hrs) at constant voltage (30 V) and at different 
annealing temperatures (no annealing, 300, 400, 500 0C). They reported that contact angle 
decreased with increasing anodization time, as shown in Figure 2.6, and increasing annealing 
temperature 119.  Also, it was reported by Uchida, et al that anatase phase of titania nanotubes 
after annealing is much more efficient for nucleation and growth of bone tissue. This is attributed 
to its ability to promote growth of hydroxyapatite layer 120.    
 
 
Figure 2.6: Contact angle of titania nanotubes surface versus anodization time 119. 
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Influence of nanoarchitecture on bioresponse for intravascular stent surfaces are not as 
thoroughly reviewed in literature as for orthopedic prosthesis. Yet, a significant number of 
research groups have investigated the effect of rough topographies on stent surfaces for almost 
two decades now, and attention has been paid lately to nano-scale treatment. Back in 1997, De 
Scheerded, et al suggested that stents with electropolished smooth surfaces are less thrombogenic 
than non-polished ones. This was demonstrated on a rat AV (atrioventricular) model and a 
porcine coronary model using an electropolished sample versus untreated one. Total weight of 
the formed clot was found to be much lower with electrochemically polished sample 121. Tepe, et 
al used an in-vitro model with human fresh whole blood to study hemoresponse of 
electropolished stent surface reaching the same conclusion. It was found that platelet activation 
and thrombogenicity was reduced on such treated samples versus smoother ones 122. These 
reports can significantly discourage the use of rough surface in stent applications, despite its 
promising potential for offering polymer-free drug loaded surfaces. 
 
However, on the other side, Palmaz, et al were able to demonstrate faster endothelialization 
on stent surface decorated with parallel grooves at the microscopic scale than smooth 
counterpart. This was studied using in-vitro culture of endothelial cells 123. They, furthermore, 
confirmed their results using in-vivo studies through placing sample stents in porcine carotid 
arteries 124. They explained stating that microscopic grooves assisted endothelial cell (EC) 
migration to stent surface, which was found to be more influencing in endothelialization than EC 
proliferation 125. This fast endothelialization on rough topographies was found to significantly 
reduce rates of thrombosis as well as neointimal hyperplasia. However, delayed 
endothelialization with their smooth counterpart has been linked with late intravascular 
complications 26,126–130. These findings strongly supported studies that were extensively 
undertaken on stent rough surface treatment for enhancing drug eluting stents.  
 
These efforts were initially invested in studying the biological interaction of microporous 
surface architectures fabricated by different techniques. Doi, et al demonstrated positive 
influence of microporous polyurethane surface treatment on endothelial tissue response using in-
vitro analysis 131. Also, Nakayama, et al supported this data by in-vivo studies. They covered the 
stent surface with microporous elastomeric film – fabricated by laser ablation – with 
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immobilized FK506 for prevention of neointimal hyperplasia. After one month implantation in 
rabbits, no significant lumen loss or hyperplasia was observed 132.  Dibra, et al performed an in-
vivo evaluation as well but on human sample, they conducted a randomized double blind study to 
investigate the influence of stent surface topography on patient outcome after stent implantation. 
They used 316L SS stent roughened with sand blasting into 0.09 and 0.21 µm minimum and 
maximum root mean square roughness reference to a smooth surfaced stent. Data reported from 
this study encouraged the use of rough surface treatment not only due to ability to significantly 
reduce late lumen loss versus smooth reference, but also due to its potential to be used for 
storage of anti-restenotic drugs 133. Transferring micro-scale stent surface treatment into the 
market, Yukon™ stent was released by Translumina, Hechingen, Germany. Post marketing 
clinical data demonstrated comparable performance with other well-established stent (Taxus), 
while failed to prove non-inferiority with another (Cypher). Therefore, long term efficacy and 
safety of Yukon stent is still under question and investigation.   
 
For higher pores density, larger surface area, more controlled drug release profile and better 
biomimicry, nanoporous surfaces on stent materials became highly attractive for investigation 
134. Wieneke, et al coated a 316L SS stent with aluminum thin layer then electrochemically 
converted it into nanoporous structure with pore diameter from 5 to 15 nm. They investigated the 
effect of this architecture loaded with tacrolimus drug on the biological response of surrounding 
tissue. They reported that the coating as well as loaded drug resulted in a positive synergistic 
effect reducing the local inflammatory response and intimal hyperplasia, as seen in Figure 2.7 
135. This led to the release of Jomed™ stent into the market of intervention cardiology 136. 
However, Kollum, et al carried out in-depth investigation to assess the effect of this nanoporous 
aluminum coating on in-stent restenosis, using porcine restenosis model. Particle debris was 
found to be shed from the coating into the media and the intima, resulting in augmented 
inflammatory response. This can potentially counteracts the effect of the antiproliferative loaded 
drug resulting in neointimal hyperplasia and late lumen loss, see Figure 2.8 137. 
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Figure 2.7: Inflammatory cells migration to stent strut. A) Bare metal stents. B): with Al2O3 coating. 
C): with Al2O3 coating loaded with tacrolimus 60 µg. D): with Al2O3 coating loaded with tacrolimus 120 
µg 135 
 
 
 
Figure 2.8: Cross sectional histomorphometric images of porcine arteries 4 weeks after implanting A) 
bare stents, B) aluminum oxide ceramic-coated stents, C) aluminum oxide ceramic-coated stent eluting 
FK506 (50 µg)  D) aluminum oxide ceramic-coated stent eluting FK506 (180 µg)  . Presenting: A) thin 
neointima; well healed. B) Thick neointima with fragments of ceramic stent coating present (arrow, 
right). C) moderately thick neointima; well healed with fragments of ceramic stent coating (arrow, right). 
D) neointima; well healed and similar in area to bare metal stent with fragment of ceramic stent coating 
(arrow, right) 137.  
34 
 
On the other hand, the use of TiO2 nanotube arrays for stent surface treatment showed highly 
promising biological response that has driven its thorough investigation for the last few years. 
Jin, et al have reported in 2008 an enhanced endothelial cells migration, faster proliferation and 
increased reliability in the presence of TiO2 nanotubes. They underwent in-vitro analysis using 
bovine aortic endothelial cells (BAEC) to compare between flat Ti surface versus nanostructured 
oxide counterpart. They observed enhanced focal cells adhesion, contact stimulation and an 
upregulated antithrombotic state with the nanoarchitectured surface, see Figure 2.9 138.   
   
 
Figure 2.9: BAECs viability on flat Ti (upper panel) versus TiO2 nanotubes (lower panel) after 
different time intervals (6, 12, 24, 48 hours). Cell survived over the two substrated, however, it showed 
more flat monolayer of cells on nanotubes at 48 hours versus aggregated and relatively disrupted ones on 
flat Ti at the same time 138. 
 
In 2009, Mark, et al used another in-vitro model to study the impact of TiO2 nanotubes on 
biological response of stent materials. The model involved studying the cellular activity of 
mesenchymal stem cells (MSC) on the nanoarchitectures. They examined the influence of not 
only surface geometry, but also surface chemistry and crystallinity. Their data reported 
significant dominance of effect of geometry over other parameters on biological response. Data 
supported better cells migration, adhesion and proliferation on TiO2 nanotubes versus smooth 
surface. Furthermore, they observed enhanced MSC differentiation on nanotubes with smaller 
diameter (15nm) as compared to larger diameters (about 100nm), see Figure 2.10 109. 
 
35 
 
 
 
Figure 2.10: MSC adhesion to 15 and 100 nm TiO2 at high and low F- content at 2 time intervals 109. 
 
 
These findings were supported by Desai, et al by immunofluorescence staining, SEM 
imaging, proliferation assay, and immunoassay using endothelial cells (EC) and vascular smooth 
muscle cells (VSMC) cultures. Results suggested that nanotopography may influence EC and 
VSMC in a manner useful for vascular stents applications. As shown in Figure 2.11, TiO2 
nanotubes promote EC proliferation, which would result in faster healing, while does not support 
VSMC proliferation, which would result in lower risk of neointimal hyperplasia 139. One year 
later they further reinforced these data using gene expression analysis. Microarrays indicated 
positive effect on EC proliferation and favored negative effect on VSMC proliferation, and 
expression of inflammatory precursors and well as coagulation involved molecules 140. 
 
 
 
36 
 
 
 
Figure 2.11: Ratio of 5-ethynyl-20-deoxy- uridine (EdU) positive, which is incorporated to detect cell 
proliferation according to the assay protocol. (A) ECs, (B) VSMC on nanotubes versus smooth muscles, 
normalized by the average proportion of positive cells on flat surfaces on day 1 and 3. Data is presented 
as average + or - standard deviation. *p<0.05, **p<0.01 versus same day flat control, n=6 139. 
 
 
As blood contacting biomaterials, hemocompatibility is an essential property to be 
investigated for TiO2 nanotubes as part of evaluating its biological response. Smith, et al have 
investigated the adhesion and activation of platelets, clotting kinetics of whole blood and key 
blood serum proteins adsorption on titania nanotubes arrays. Their initial results reported high 
protein adhesion, platelets activation and whole blood clotting kinetics. However, they 
highlighted that hemoresponse is highly affected by surface geometry and can be altered and 
adjusted by controlling tubes size parameters, which required further proper investigation in this 
area 57. On the other hand, Menon, et al suggested that enhanced proliferation of endothelial cells 
on grown TiO2 nanotubes would consequently contribute to hemocompatibility through 
regulating platelet activation and accordingly reducing the risk of thrombosis. This was 
elaborated by highlighting that one of the main roles of endothelial cells is to secrete anti-
thrombogenic products such as nitric oxide (NO) and prostaglandin I2 (PGI2), which help 
maintaining vascular homeostasis 141.     
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2.3. Nanoarchitectures as drug reservoirs 
 
As mentioned previously, the great interest of using nanoscale topographies on the surface of 
biomaterials is not only driven by their ability to enhance biological response, but also by their 
high potential to be used as drug reservoirs for local drug delivery. Choice of the drug active 
ingredient is directly related to the application and site of biomaterial implantation. For example 
local delivery of antibiotics is applied for orthopedic implants to ensure environment sterility and 
ensure proper healing. On the other side, for intravascular stents, for example, cytotoxic drugs 
are mostly delivered locally to avoid neointimal hyperplasia and preserve blood flow. Local drug 
delivery does not only target the dosage to the site of application but also avoid higher risks of 
side effects associated with systematic drug intake 142,143. Nanoarchitectures as local drug 
delivery systems can offer a number of advantages over few of currently followed techniques; 1) 
It can be grown on material whose biocompatibility has been well-established and already 
widely used for biomaterials such as titanium and titanium-based alloys, 2) synthesis techniques 
can provide a control over the surface structure's size and morphology, offering potential control 
over release kinetics, 3) nanoarchitectures can be fabricated on 3 dimensional (3D), non-planar 
surfaces, hence being adaptable to a variety of implant technologies, 4) and surface wettability 
can be easily controlled 143.  
 
For intravascular stents, local drug delivery using nanoarchitectural reservoirs was first 
investigated by Wieneke et al in 2003. They used nanoporous anodic aluminum oxide (AAO) to 
release tacrolimus for studying rabbit intimal proliferation 135. Positive results have driven the 
interest of Kim et al in 2007 to further investigate the drug release kinetics from such structures. 
316 SS stents were coated with nanoporous anodic aluminum oxide (AAO) fabricated via 
anodization, which have different tubes dimensions (diameter and length). 2-deoxyadenosine 
drug was loaded to the (AAO) coated sheets by immersion in drug solution for certain amount of 
time. In-vitro drug release was investigated in phosphate buffer saline (PBS) using high 
performance liquid chromatography (HPLC). It was observed that drug release is directly 
proportional with nanotubes pore diameter, while inversely proportional with their depth, see 
Table 2.3 144. In another study, Kim et al used lipophilic paclitaxel drug loaded in the same AAO 
platform to study its release kinetics, versus the hydrophilic 2-deoxyadenosine. Paclitaxel release 
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from different nanotube diameters and depths showed that amount of drug released did not 
depend on pore diameter but varied inversely with depth, see Figure 2.12 145.    
 
Table 2.3: Amount of drug release/µg from AAO film 144. 
 
 
Time 
(hour) 
Diameter (nm) 
26.46 13.5 19.7 13 27.2 
Depth (μm) 
1.33 0.943 1.4 3.2 4.4 
2 
5 
11 
23 
47 
95 
143 
500.97548 
3.15701 
0.75078 
0.9379 
1.08203 0 0 
0 
0 
397.58979 
3.00 
0.4815 
0.40268 
0 
0 
0 
197.72221 
0.93224 
2.17619  
0.93244  
0.49764  
0 
0 
573.01701 
2.81911 
0.3778 
0 
0 
0 
0 
304.32572 
2.39437 
0.37863 
0 
0 
0 
0 
 
 
Figure 2.12: Cumulative release of paclitaxel from AAO with different pore diameter (to the left) and  
depths (to the right) 145. 
 
However, data on biological studies of nanoporous alumina versus titania nanotubes 
described earlier could possibly indicate better in-vivo response with titania nanoarchitectures 146. 
This encouraged their in depth investigation as drug reservoirs for a number of applications 
including intravascular stents, some of which are summarized in Table 2.4 below. This was early 
studied by Ayon et al using nanoporous TiO2 to load dexamethasone drug with target value 
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comparable to dexamethasone-eluting BiodivYsioTM stent. They reported that with fabricated 
structural dimensions, one step loading resulted in unfavourable value of loaded drug with 70 
ng/mm2 versus target of 500 ng/mm2. However, subsequent and sequential drug loading 
procedure would increase total loaded amount and potentially reach desired target, as seen in 
Figure 2.13 below 147. 
 
 
Figure 2.13: Amount of loaded dexamethasone per sequential loading, using HPLC 147. 
  
Popat, et al investigated the use of TiO2 nanotubes as another nanoarchitecture that can act as 
drug reservoir. Through fabrication strategies, they offered better control over drug loading 
capacity and release kinetics through controlling nanotubes dimensions.  In one study, they 
fabricated TiO2 nanotube arrays of 80 nm pore diameter and 400 nm in length for loading 
Gentamicin antibiotic to avoid bacterial infection at site of bone implants. They reported that 70-
85% of the drug was retained in the nanotubes after washing. For drug release they reported that 
total time needed for all drug to be eluted from the array is directly proportional to the initial 
loaded amounts, with total time of 45, 90, 150 minutes taken to release 200, 400, 600 μg 
gentamicin respectively 148. In another study, Popat, et al studied the drug release rate by varying 
the loaded amount and the drug molecules polarity. They used two different loaded 
biomolecules; 1) Bovine serum albumin (BSA) with molecular weight 67 kDa and net charge -18 
at pH 7, 2) and Lysozymes (LYS), with molecular weight 14 kDa and net charge +7 at pH 7 143. 
They used three different initial loaded amounts of BSA and LYS; 200, 400, 600 μg, and 
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expressed the loading efficiency as percentage of the loaded protein after washing. The results 
showed that 60-80% of protein is loaded in the nanotubes regardless of the initial loading, see 
Figure 2.14. Their release profile demonstrated that release kinetics can be also controlled by 
varying nanotubes diameter and length 143.  
 
Table 2.4, summarizes some of the ongoing efforts that are being exerted to study drug 
loading and release kinetics for TiO2 nanoarchitectural reservoirs. Studies included are reporting 
a wide range of therapeutics for different biomedical applications, such as anti-inflammatory, 
antibacterial, anticancer and immunosuppressants. Factors, which affect drug delivery 
functionality, including nanotubes morphology, dimensions (diameter and length), surface 
chemistry, loaded drug properties, hydrophilicity …etc are described. 
 
 
Figure 2.14: Loading efficiency of BSA and LYS at different initial loaded amounts 143. 
 
 
Table 2.4: Summary of using TiO2 nanotubes for delivering selected therapeutics 146. 
Main Target Therapeutic loaded Additional features Ref 
 
Antibacterial 
 
 
 
 
 
 
Vancomycin 
Penicillin/streptomycin 
Gentamicin  
Cefuroxime 
Silver nanoparticles  
Zinc ions 
 
In-vivo studies 
Loaded using simulated body fluid 
Osseointegrating 
 
Osseointegrating/in-vivo studies 
Osseointegrating & anti-inflammation   
 
149 
150 
148 
151 
152 
153 
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Anti-inflammatory 
 
 
 
 
 
 
 
 
Antifungal 
 
Osseointegrating 
 
 
 
 
 
 
 
 
 
 
 
 
Anticancer 
 
 
Antimicrobial peptide  
hhc-36  
Enrofloxacin 
 
Ibuprofen 
 
Indometacin 
Indometacin loaded and 
chitosan/poly(lactic-co-glycolic 
acid) coated 
Naproxen 
Dexamethasone  
 
Itraconazole 
 
Gelatin stabilized gold- NPs 
Bone morphogenetic- protein-2 
(BMP2)  
Pamidronic acids 
 
Pre-synthesized- hydroxyapatite  
Strontium 
Bisphosphonates (BPs) 
 
C-terminal (connective- tissue 
growth factor)- fragment  
Doxorubicin 
 
Selenium  
Paclitaxel  
Cisplatin 
Also targets antibiotic-resistant 
bacteria 
 
 
Osseointegrating/mechanical stability 
studies 
 
Antibacterial and osseointegrating 
 
 
 
Loading using simulated body 
fluid/osseointegrating 
 
 
 
 
 
Treatment of osteoporosis and Paget’s 
disease 
 
 
 Study on Ti-6Al-4V alloy surface/ In-
vivo investigations 
 
 
 
 
Antibacterial and osseointegrating  
 
Osseointegrating 
154 
 
155 
 
156 
 
157 
157 
 
 
 
158 
159 
 
160 
 
161 
 
162 
 
163 
164 
165 
 
166 
 
167 
 
168 
169 
170 
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Immunosupressant 
 
Neurotransmitters 
 
Sirolimus  
 
Dopamine 
 
Study on vascular smooth muscle cells  
 
Implantable drug delivery system for 
brain conditions 
 
171 
 
172 
 
Furthermore, many techniques were investigated to enhance drug loading and release rates 
from TiO2 nanotubes. These are diagrammatically represented in Figure 2.15 and included for 
example, (A) precise control over length and diameter, (B) surface chemistry, (C) using plasma 
polymerization for tuning pore opening, (D) applying degradable polymeric coating on pore 
surface, (E-F) loading with drug nanocarriers that may be used for multiple drug delivery as 
well, (G-I) triggering drug release using external field, such as, magnetic field, temperature, 
radiofrequency and ultrasound 146.  
 
 
Figure 2.15: Strategies for enhancing drug release from TiO2 nanotubes (visualized using one 
nanotube) 146. 
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Chapter 3: Materials and Methods 
 
3.1. Materials and Supplies 
 
Titanium metal foils with thickness 0.25 mm and purity 99.95% were purchased from 
Alfa Aesar, USA. Ti-45Nb alloy sheets with 45 wt% Nb and thickness of 2.5 mm were 
purchased from Allegheny Technologies, Japan. Ti-17Nb-6Ta of thickness 0.3 mm were 
received as prepared by Department of Materials Science and Engineering, Egypt-Japan 
University of Science and Technology (E-JUST), Egypt, which was prepared by arch-heating 
in argon gas (high purity) atmosphere. It was then homogenized at 1000 o C for 7.2 ks in same 
atmosphere. Subsequently, samples underwent cold-rolling by 90% thickness reduction (CR).   
Ammonium fluoride (ACS reagent, ≥ 98.0%), Formamide (purum, ≥ 98.0% (T)) and 
Glycerol (ACS reagent, ≥ 99.5%) were purchased from Sigma Aldrich, USA. Ethylene Glycol 
(Pure P.A.) was purchased from Lab-Scan analytical sciences, Poland, while Ammonium 
Sulphate (Ex-Pure) was purchased from Oxford Laboratory, India. Hydrochloric acid (35-38%) 
was purchased from Alpha Chemika, India. Sulphuric acid (98%), phosphoric acid (98%) and 
perchloric acid (70% AR) were purchased from S D Fine-Chem Limited, India.  
2’- Deoxyadenosine drug (99%) and phosphate-buffered saline (PBS, 1X), sterile liquid 
were purchased from Alfa Aesar, Germany.  
 
3.2. Potentiostatic Anodization 
 
Anodization technique was used to fabricate arrays of Titanium and Titanium alloy 
nanoarchitecture. Prior to the anodization process, Ti and Ti-alloys sheets were cleaned 
ultrasonically in acetone then ethanol then distilled water. Platinum foil was washed in dilute 
HCl then distilled water. The anodization electrochemical setup is built up from counter 
electrode (platinum foil or graphite rod was used) and a working electrode of the substrate 
material of interest (cleaned Ti and Ti- alloy sheets). Electrodes were immersed in different 
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fluoride containing electrolytes in room temperature. Mixtures of different aqueous and organic 
electrolytes that were used are summarized in Table 3.1 below. 
 
Table 3.1: Summary of the anodization process conditions used for different substrates and/or to obtain 
different morphology of nanoarchitectures 
Electrolyte Code* Electrolyte composition Voltage/V  Time/hour 
PD1 0.2 M NH4F and 0.1 M H3PO4 , then complete 
to final volume of 50 ml with distilled Water 
20  1.5 
FP2 0.2 M NH4F + 3 vol % H2O + 0.1 M H3PO4, 
then complete to final volume of 50 ml with 
formamide 
30  1.5 
 
FG3 0.35 M NH4F + 5 vol % H2O + 20 vol% 
formamide, then complete to final volume of 50 
ml with glycerol 
50  3 
2 
AD4 0.11 M NH4F + 1 M (NH4)2SO4, then complete 
to final volume of 50 ml with distilled water 
40  2 
 
*Electrolyte code: (Two main electrolyte components plus a serial numerical value) 
 
Constant voltage between the counter and the working electrodes was applied using 
E3641A key sight DC power supply for predetermined amount of time. Voltage and time 
differed with the electrolyte used and are also summarized in Table 4.1. After anodization, 
samples from aqueous electrolytes were ultrasonicated in distilled water, while those from 
organic electrolytes were sonicated in acetone. Sample were afterward left to dry in air. Figure 
3.1 demonstrates the setup used for this experiment and described above.  
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Figure 3.1: The two-electrode potentiostatic anodization setup. 
 
3.3. Surface Polishing 
 
In attempt to enhance nanoarchitecture morphology and avoid the effect of surface oxide 
layer on final structure, different surface polishing techniques were tried: 
 
3.3.1. Mechanical Polishing 
 
Mechanical polishing was done either manually or automatically. For manual polishing, 
samples were fixed manually on a smooth surface and gently rubbed with grinding paper (600 
grit/inch2). For automated mechanical polishing, samples were fixed on a metallic stage using 
heated wax. Samples were exposed to grinding wheel with 600, 800 and 1200 grit/inch2 silicon 
carbide papers, respectively and then treated with alumina of 0.5 µm. After polishing, samples 
were detached from the metallic stopper by immersion in acetone under ultrasonication.  
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3.3.2. Electrochemical Polishing 
 
System used for electrochemical etching is the same as described previously in 
potentiostatic anodization sector and demonstrated in Figure 4.1. However, the difference 
between the two setups would be in the used electrolyte solution, voltage and time. Two different 
systems were explored for electrochemical etching of desired samples.  
System #1: Electrolyte of 30 vol. % H3PO4 and 70 vol. % ethyl alcohol is used. Solution 
is stirred using heating magnetic stirrer, AREC at 500 rpm. The electrochemical setup is 
surrounded by ice for temperature adjustment to 0 o C. Potential of 60 V is applied for 20 
minutes. 
 
System #2: Electrolyte of 20 vol. % HClO4 and 80 vol. % acetic acid (C2H4O2) at room 
temperature is used. Potential of 35 V is applied for 4 minutes. 
 
3.3.3. Chemical polishing 
 
Chemical etching was done using etching system of hydrofluoric (HF) and nitric acid 
(HNO3). Prepared etching solution consisted of 5 vol.% HF, 15 vol% HNO3, 80 vol.% distilled 
water. Samples were immersed in the etching solution for 10-15 minutes. After removal, it was 
cleaned with distilled water under unltrasonication for 1 minute. 
 
3.4. Morphological characterization 
 
Images were obtained for morphological characterization of Ti and Ti-alloys samples 
fabricated and treated with different conditions, using Field Emission Scanning Electron 
microscope. FESEM, Leo Supra 55 – Zeiss Inc., operated at 9.00 kV, was used to capture these 
images. Images were used to detect the success of nanoarchitecture fabrication, measuring 
dimensions, and study the effect of surface treatment prior and after anodization. FESEM was 
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also used to study cell proliferation on different samples morphology as will be explained in a 
later section. Finally, it was used to detect the accumulation of drug on sample surfaces post drug 
loading experiment.  
Only samples upon which is attached the cell culture are gold-sputtered before imaging to 
enhance conductivity for better imaging. Otherwise, all samples were imaged as is. 
 
3.5. Thermal Annealing 
 
As required, as-anodized samples were thermally annealed in a furnace for a pre-
specified time. They were subjected to a temperature of 450 oC in air, with ramping heating rate 
of 1 o C/min. Samples were annealed either prior to some characterization techniques, including 
XRD, second run for the nanoindentation and number of FESEM-characterized samples, or as 
surface treatment for controlling surface oxide layer. Steady temperature of 450 oC was 
maintained for time interval of 2, 3 or 4 hours according to the purpose of the treatment. Furnace 
used was Lindberg/Blue MTM Tube furnace, Thermo scientific, as shown in Figure 3.2. 
 
 
Figure 3.2: Lindberg/Blue MTM Tube furnace, Thermo scientific, used in samples annealing. 
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3.6. Structural and Compositional Characterization 
 
Four different techniques were used to identify and confirm structure and/or composition of 
fabricated NTs layer on Ti-17Nb-6Ta alloy. These techniques included: 
- XRD diffractometer (D8, Brucker) with a copper tube of 1.54Å wavelength.  
- High Performance Raman Analyzer (ProRaman-L) with an excitation laser beam, 
wavelength of 532 nm. 
- Energy Dispersive X-ray Spectroscopy (EDX) detector equipped on FESEM, Leo Supra 
55 – Zeiss Inc.  
- X-ray Photoelectron Spectroscopy (XPS) on a Thermo Scientific K-alpha XPS with an Al 
anode. Spectra charged at 532 eV reference to O 1s.  
 
3.7. Mechanical Characterization 
 
Young’s Modulus and Hardness of the samples were measured before and after annealing 
(at 450 o C for 3 hours). Tests were done using Nano Indenter XP, MTS with berkovitch tip (20 
nm) creating 6 X 6 array of indentations, separated by 150 µm. Nanoindentation was done with 
CSM Tip Calibration mode, strain 0.05 S-1, depth 3000 nm and strain rate 10 nm/sec. FESEM 
was used to image the indentation projected contact area caused by the Berkovich tip. 
 
3.8. Assessment of Nanoarchitectures’ Biological Response 
 
For biological assessment vascular endothelial cells were extracted from mice umbilical 
cords and cultured in-vitro. They were used for cytotoxicity measurements, cells adhesion and 
proliferation on NTs. These tests were conducted at the holding company for biological products 
and vaccines (VACSERA) and described as follows:  
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3.8.1. Cytotoxicity Measurements 
 
Cytotoxicity was assessed for Ti-17Nb-6Ta sheets as received, with Homo-NTs and 
Hetero-NTs structures using MTT assay.  
 
3.8.1.1. Sample Preparation 
 
- Samples were incubated in shaker incubator at temperature of 37 oC in culture media 
overnight. 
- Samples’ extracts were collected after incubation. 
- Extracts were diluted serially to study cytotoxicity with MTT assay as will be described 
as follows. 
 
3.8.1.2. MTT Kit 
 
- MTT kit is based on reductive coloring reagent to detect mitochondrial dehydrogenase in 
living cells. MTT in this assay is reduced by NADH to purple formazan. 
- Needles shaped crystals colored in purple are formed by MTT formazan due to its water 
insolubility.  
- To solubilize these crystal, organic solvent is used.  This allowed measurement of 
absorbance to quantify cells viability. 
 
3.8.1.3. MTT Assay: 
 
1- Vascular endothelial cells were grown in culture media as monolayer. Media is 
supplemented with fetal bovine serum, inactivated, 10%.  
2- Cells were plated in 96-well tissue culture plate with 104 /well. They were incubated at 
temperature 37 oC with 5% CO2 in a humidified incubator for 24 hours to allow cells 
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attachment to the plate before adding samples extract. This step is excluded for blank 
wells, which is used with no cells. 
3- Different dilutions from samples extracts were added for testing cytotoxicity, except for 
cell control wells. For each concentration, eight replicates were prepared, as shown in 
plate design in Table 3.2 below. 
 
Table 3.2: Plate design used for cytotoxicity MTT assay of different nanoarchitectures versus as received 
substrate material. 
 
12 Alloy substrate   Hetero-NTs  Homo-NTs Cell 
Control 
Blank  
 2-  1-  0 2-  1-  0 2-  1-  0   A 
 2-  1-  0 2-  1-  0 2-  1-  0   B 
 2-  1-  0 2-  1-  0 2-  1-  0   C 
 2-  1-  0 2-  1-  0 2-  1-  0   D 
 2-  1-  0 2-  1-  0 2-  1-  0   E 
 2-  1-  0 2-  1-  0 2-  1-  0   F 
 2-  1-  0 2-  1-  0 2-  1-  0   G 
 2-  1-  0 2-  1-  0 2-  1-  0   H 
 
4- Cells were cultured with the added samples extracts for 48 hours at temperature 37 oC 
with 5% CO2.  
5- After 48 hours, attached viable cells were separated by discarding culture media through 
decantation. Discard media contained both samples extracts and dead cells.  
6- Plate is afterward washed twice, using PBS (pre-warmed). 
7- MTT reagent of 40 μl was added to each well including negative control wells and blank. 
8- After adding MTT, plates were incubated for 4 hours in the dark to allow for the 
reductive effect of mitochondrial dehydrogenase from viable cells to take place on MTT 
reagent. Accordingly, MTT will change into purple needles of Formazan.  
9- Purple needles of Formazan were solubilized by 150 μl DMSO, added to each well. 
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10- To determine concentration in different well, absorbance was measured with microplate 
reader (ROBONIK TM P2000 Eliza plate reader) at 570 nm. 
 
 
Figure 3.3: Diagrammatic representation of MTT assay steps 168.  
 
3.8.2. Cell Proliferation Assay 
 
The following assays were conducted to study vascular endothelial cells proliferation on 
different nanoarchitecture morphologies versus as received smooth Ti-17Nb-6Ta surface. 
Endothelial cells were plated on the three Ti-alloy samples (As received, Homo-NTs, Hetero-
NTs) with cell densities of 5000 /cm2. Cells were incubated at 37 o C with 5% CO2 and 70% 
humidity for 24 hours. Afterwards, non-adherent cells were washed away using phosphate buffer 
saline (PBS), to only leave adherent cells on surface of Ti- alloy samples. 
Cell growth was analyzed after plating by counting adherent cells at days 1, 3 and 7. Analysis 
was done by MTT viability assay (described earlier), Tryptan blue viability assay and imaging 
under FESEM as described below: 
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3.8.2.1. Tryptan Blue Viability 
 
1- The cells monolayer was detached by trypsinization with Trypsin/EDTA (Ethylene 
Diamine Tetraacetic Acid) solution (0.25%). Detached cells were re-suspended in fresh 
medium that contains fresh bovine serum. 
2- 100 µl of re-suspended cells were mixed with equal amount of tryptan blue (dilution 
factor = 2) by gentle pipetting.  
3- Hemocytometer and cover slip (shown in Figure 3.4) were thoroughly cleansed using 
70% ethanol, before sliding the cover over the chamber. 
4- 10 µl of cells suspension were added to both chambers of the hemocytometer and 
inverted microscope was used to examine cell viability. 
5- Bright non stained cells indicated viable cells, while blue stained ones indicated dead 
cells. Both types of cells were counted under the microscope to calculate percentage of 
cells viability. 
 
 
 
 
Figure 3.4: Diagrammatic representation of hemocytometer used in Trypan blue assay 169. 
 
3.8.2.2. Cell Imaging by FESEM 
 
Endothelial cells were cultured on the as anodized samples for 3 days. Afterwards, 
fixation of proliferated cells was done using gluteraldehyde, diluted with PBS. Samples surface 
were gold-sputtered at 20 mA for 1 minute, using SEM coating unit E5000, Polaron Equipment 
Limited. Samples were imaged using FESEM, Leo Supra 55 – Zeiss Inc., operated at 5.00 kV. 
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3.9. Study of Nanoarchitecture as Potential Drug Carrier 
 
3.9.1. Drug Loading 
 
Both Homo-NTs and Hetero-NTs were studied as potential drug reservoirs for the 
application of drug eluting stents (DES). Amount of loaded drug were compared between the 
two systems to determine the more favorable platform. Triplicates were prepared and examined 
for each platform to ensure reproducibility. Hydrophilic 2'-deoxyadenosine was used as the 
cytotoxic drug molecule.  
 
Steps for quantifying the percentage of drug loaded are described below: 
 
1- For each sample, known concentration of the drug solution was prepared as 1 mg 2'-
deoxyadenosine per 1 ml distilled water in a 10 ml beaker (applying sink conditions).  
2- Solution was stirred on magnetic stirrer (AREC) at 500 rpm for 2 minutes till complete 
solubility.  
3- One side of the as anodized cleaned samples were covered by an insulating material to 
ensure drug loading into one side of the Ti-based anodized sheets. 
4- Samples of 1 cm2 were immersed in the prepared solution and left for 36 hours without 
stirring.  
5- After the 36 hours, samples were removed from the drug solution and left to dry in air for 
12 hours. 
6- Insulating material was removed from the samples. 
7- Each of the samples loaded with drug was immersed in a 10 ml beaker, containing 10 ml 
PBS under magnetic stirring for 3 minutes at 700 rpm. 
8- 1 ml of the PBS were withdrawn from the beaker using a pipette and its absorbance was 
measured using CARY 500 scan, UV-Vis-NIR spectrophotometer at 260 nm. 
9- For calculating the unknown concentration of drug released into the PBS, calibration 
curve presented in Figure 3.5 was used. For preparing the calibration curve, serial 
dilutions of known concentrations of the drug in distilled water were prepared and their 
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absorbances were measured at 260 nm. Absorbance was plotted versus concentration 
with setting trend line interception to zero.  
 
 
Figure 3.5: Calibration curve of 2'-deoxyadenosine in distilled water. 
 
 
3.9.2. Drug Release Computational Study 
 
Drug release profile from NTs was theoretically predicted using computational simulation. The 
model was built using COMSOL Multiphysics ® 4.1 modeling software. To simulate the 
kinetics of drug release from the NTs, “Transport of diluted species” module was used, with 
Fick’s law equation governing the drug motion. Boundary conditions stated that flux outside the 
boundaries of the NTs and the tissue is equal to zero.    
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Chapter 4: Results and Discussion 
 
Reference to the challenges currently facing drug eluting stents, which were discussed 
earlier in chapter 1, the need for surface optimization of stent materials is considered crucial. 
Efficient surface composition and morphology should allow controlled endothelial tissue healing 
to avoid late thrombosis. On the other side, it should offer an ability to act as a drug carrier for 
local drug delivery to avoid neointimal hyperplasia and vessel restenosis. This chapter covers the 
results and discussion of the work undertaken to fabricate a nanoarchitectured system that shall 
enhance tissue proliferation and can possibly act as drug reservoir. 
4.1. Fabrication of Highly Ordered Arrays of Ti and Ti-Alloys 
Nanoarchitecture 
 
As discussed in chapter 2, few attempts were conducted to study the use of nano-surface 
morphology for the use in drug eluting stents. However, reported results studied 
nanoarchitectures fabricated from a material coated on the main stent substrate material. This is 
done for two main reasons: 1- due to the sensitivity of the application to the material mechanical 
properties. Stent material needs fine adjustment and tradeoff between mechanical properties 
affecting the stent flexibility and strength that was not offered by the coating material alone. 2- 
The coating was used as a biocompatible insulator between the vessel tissue and stent substrate 
material that can possibly release cytotoxic metal traces. Nevertheless, self-grown 
nanoarchitectures from the stent substrate can potentially be of greater benefit than different 
coating-substrate materials. This shall reduce the number of processing steps required for 
material coating and prior treatment to enhance adhesion. Self-grown layer would better avoid 
stresses gradient and allow for better stronger bond. 
In an attempt to present this self-grown system, fabrication of nanoarchitectures on Ti-
17Nb-6Ta alloy was investigated. Ti-17Nb-6Ta alloy is a potential material for self-expandable 
stent that is meeting the biocompatibility and mechanical properties required for such 
application. Their mechanical properties are comparable to Nitinol, which is currently the most 
widely used material for self-exandable stents. Ti-17Nb-6Ta alloy has a Young’s modulus of 68 
GPa, ultimate tensile strength (UTS) of 700-1050 MPa, Elongation of 10-30% and corrosion 
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resistance of -44.1 Ecorr (mV). Furthermore, the tantalum content can possibly enhance radio-
opacity and stent visibility during PCTA due to its relatively high density. To fabricate ordered 
morphology of nanoarchitectures on Ti-17Nb-6Ta ternary alloy, Ti pure and Ti-Nb binary alloys 
were first investigated for optimization.  
4.1.1. Pure Ti as Nanoarchitecture Substrate 
 
Both aqueous and organic electrolytes for anodization setup were investigated. For 
aqueous conditions, electrolyte PD1 from Table 3.1 was used. While for organic conditions, 
electrolytes FP2 and FG3 were used.  Figure 4.1 shows FESEM images for the as-anodized 
nanotubes arrays. Aqueous electrolyte resulted in the formation of nanotubes (NTs) that are 
distributed over the entire substrate. The NTs diameter varied widely along the layer (from 70 to 
100 nm). However, outer diameter was observed to be irregular in structure with circumferential 
serration and ridges, which is common with aqueous electrolytes. Hence, organic electrolytes 
were investigated to optimize the NTs morphology, including alignment, dimensions and wall 
regularity. 
   
Figure 4.1.: Top view FESEM images of as-fabricated TiO2 NTs anodized in aqueous electrolyte at (A) 
higher and (B) lower magnification. 
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Regarding the use of organic electrolyte, first, formamide-based electrolyte (FP2) was 
used. As shown in Figure 4.2. (A) and (B), the NTs structure was observed to be more defined. 
NT diameter became more uniform (110 ± 10 nm). However, circumferential serration is still 
observed. Furthermore, nanotubes are slightly bent inwards forming nanoscaled islands, 
distributed along the substrate. Reducing the formamide content was followed for glyceol-based 
electrolyte (FG3). It can be seen in Figure 4.2 (C) and (D) that NTs were significantly enhanced 
towards more vertical alignment and smoother surface.  
   
 
Figure 4.2.: Top view FESEM images of as-fabricated TiO2 NTs in formamide based electrolytes at (A) 
lower and (B) higher magnification, and glycerol based electrolytes (C) lower and (D) higher 
magnification. 
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4.1.2. Ti-45Nb Alloy as Nanoarchitecture Substrate 
 
Aqueous and organic electrolytes were explored for the anodization process of Ti-Nb 
alloy to study the effect of electrolyte type on surface morphology. For aqueous-based 
electrolytes, AD4 electrolyte was used at 40 V for 2 hours. It is evident from the FESEM images 
of Figure 4.3 that vertically aligned nanotubes were successfully fabricated.  
      
 
Figure 4.3.: FESEM images of as-fabricated NTs of Ti-45Nb obtained in aqueous (AD4) electrolye. (A) 
and (B) are top views of the NTs at high and low magnification, respectively, showing NTs 
heterogeneous dimensions and well distribution. (C) Side view of the NTs from imaging the sample at 90 
degrees, showing the circumferential serration. (D) Side view of the NTs layer through imaging a 
detached area, showing the NTs base and the layer total length. 
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Although the NTs are more defined, they still have circumferential serrations. It was also 
observed that the NTs are well-distributed over the substrate with heterogeneous dimensions 
within the same layer. NTs inner diameter varied widely between 75 and 145 nm, while the NTs 
wall thickness ranged between 5 and 20 nm. The measured thickness of the NTs layer (as shown 
in Figure 4.3 (D)) was found to be of average 5 µm despite of observed irregularity. 
As described earlier, the NTs morphology was significantly enhanced with glycerol-
based relative to formamide-based electrolytes in case of pure Ti. Accordingly, Ti-45Nb sheets 
were anodized using FG3 electrolyte. When as-anodized samples were imaged under FESEM, 
thick oxide layer was observed covering the NTs layer, which can negatively affect the NTs 
functionality for the specified application. As shown in Figure 4.4 (B), well-defined NTs can be 
seen beneath the oxide layer. Anodized samples were therefore further cleansed for longer 
amount of time. They were ultrasonicated in acetone for 30 minutes and imaged again. 
     
 
Figure 4.4: Top view FESEM images of as-anodized Ti-45Nb sheets in FG3 electrolyte. (A) Thick porous 
oxide layer formed on the surface of the NTs and (B) arrow points to the well-defined NTs beneath the 
oxide layer. 
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It can be clearly seen from Figure 4.5 that sonication for long duration successfully 
removed the undesired oxide layer without compromising the nanoarchitectured layer. Highly 
ordered vertically oriented assemblies of nanotubes were revealed. They appear as closely 
packed NTs with almost fused walls at the surface between adjacent NTs.  They are assembled 
into honey-comb like islands separated by grooves. It can be observed that NTs walls are highly 
uniform and free from circumferential serration.  
 
Figure 4.5: FESEM images of Ti-45Nb honey-comb like nanoarchitectures, fabricated using glycerol-
based electrolytes. (A) and (B) top view images of low and high magnification, respectively, and (c) side 
view from detached area after surface scratching.  
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Furthermore and most importantly for the intended application; the NTs are 
homogeneous in structure and dimension. Measured inner diameter is of average 90 ± 10 nm and 
fused walls thickness of 11 ± 2 nm.  Detached area from the NTs layer was imaged showing the 
layer side view in Figure 4.5 (C). It showed long highly uniform vertically aligned NTs with 
average length of 14 µm. It is evident from the figure that dimension of the tubular structure is 
nearly uniform throughout the tubes’ length.  
 
4.1.3. Ti-17Nb-6Ta as Nanoarchitecture Substrate 
 
Based on the extremely promising results obtained from using FG3 electrolyte with Ti-45Nb 
alloy, it was studied with the Ti-Nb-Ta alloy sheets to reproduce such ordered nanoarchitectural 
structure from Figure 4.5. As received samples were anodized using the same conditions of FG3 
electrolyte mentioned in Table 4.1. First outcome resulted in the morphology observed in Figure 
4.6. It showed highly rough layer that is totally covering the substrate. Evidence of NTs 
assembly were clear from Figure 4.6 (B) and (C) where NTs were seen either detached or 
underneath the rough surface. However, this structure can completely hinder the functionality of 
the nanoarchitecture and it is essential to remove it. Cleaning attempts using ultrasonication for 
long duration failed to overcome this problem and other techniques needed to be explored.  
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Figure 4.6: FESEM images of (A) high rough surface on as anodized samples, (B) NTs beneath the layer, 
and (C) detached NTs assembly. 
 
Referring back to the thermal history of the received Ti-17Nb-6Ta alloy sheets, it was 
found that they were oxidized at high temperature of about 800 o C. This is sufficient to result in 
a thick oxide layer prior to any electrochemical processing. As received samples were therefore 
imaged prior to anodization to examine surface roughness and optimize accordingly. As shown 
in Figure 4.7 highly rough surface was observed on Ti-17Nb-6Ta substrate. This rough structure 
can most probably remain persistent after anodization and cause the observed rough layer 
covering the nanotubes. Prior anodization processing was therefore essential to prepare the 
sample for NTs fabrication. Accordingly, sample polishing prior to anodization was studied 
through a sequence of different techniques with varying outcomes. 
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Figure 4.7.: Top view of FESEM images for as received Ti-17Nb-6Ta alloy sheets prior to anodization, at 
(A) lower and (B) higher magnification. 
 
4.1.3.1 Mechanical Polishing 
 
Manual polishing was first explored using grinding paper to gently polish the surface 
manually prior to anodization. Samples were afterwards anodized using FG3 electrolyte 
conditions. For as anodized samples, FESEM images showed improvement in surface 
morphology. Highly rough surface was not observed anymore. However, it was replaced by 
another morphology of oxide layer covering almost all the substrate surface. This layer can be 
described as thick nanoporous oxide layer with NTs of thick walls appearing beneath, as shown 
in Figure 4.8. 
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Figure 4.8: Top view FESEM images for pre-polished anodized Ti-17Nb-6Ta sheets, showing 
nanoporous oxide layer covering the underneath NTs at (A) low and (B) high magnification. 
 
In attempt to avoid the build-up of the oxide layer, manual polishing was replaced by 
automated mechanical polishing described in chapter 3. Samples were anodized post polishing 
using FG3 electrolyte with the same conditions previously described. As shown in Figure 4.9 
(A), it was found that density of thick nanoporous oxide layer from Figure 4.8 decreased 
significantly. It showed larger pores diameter with thinner walls in between. Furthermore, NTs 
appearing beneath the layer became more uniform and vertically oriented, as shown in Figure 4.9 
(B). The anodized layer, including both oxide layer and underlying nanotubes, was removed by 
ultrasonication in acetone for 30 minutes. Another step of anodization was performed on the 
same sample in attempt to guide a more uniform assembly of nanotubes, using the same 
electrolyte. As observed in Figure 4.9 (C), the less dense oxide layer appeared only in scattered 
areas along the substrate surface after second anodization. And large areas of nanoarchitectures 
started to be revealed. However, various morphologies of nanoarchitecture was observed in 
different areas along the sample, as shown in Figure 4.9 (D). These non-uniform assemblies can 
hinder the control over the intended outcome during application.  
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Figure 4.9: Top view FESEM image of the two steps anodization of Ti-17Nb-6Ta sheets after automated 
mechanical polishing. (A) and (B) shows the less dense nanoporous oxide layer covering the nanotubes at 
higher and lower magnification respectively. Arrow on image (B) shows uniform vertically oriented NTs 
beneath the oxide layer. (C) and (D) shows resulted structure from second anodization after removing the 
as anodized layer from step one using ultrasonication. (C) Shows that larger area of NTs started to reveal 
leaving the oxide layer with significant distance apart. (D) Covers different NTs morphology that was 
observed along the same substrate. 
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4.1.3.2. Electrochemical Polishing 
 
In order to avoid surface abrasion, strains and contamination that can potentially be 
caused by mechanical polishing, electrochemical polishing was explored to optimize pre-
anodization surface treatment. Two electrochemical setups were studied as described in chapter 
3, followed by samples anodization using FG3 electrolyte. System #1 that used phosphoric acid 
at 30 vol. % was not successful in avoiding the oxide layer formation on the NTs surface. It can 
be seen in Figure 4.10 that pre-treatment with system #1 resulted in uniform NTs with relatively 
thick wall underlying a low-porosity oxide layer. The assemblies, however, showed islands-like 
morphology, separated by grooves characteristic for FG3 electrolyte.    
 
 
 
Figure 4.10: Top view FESEM images of as anodized Ti-17Nb-6Ta sheets after pre-anodization treatment 
using system #1 electrochemical anodization. (A) higher magnification showing uniform, vertically 
aligned nanotubes below the oxide layer. (B) lower magnification showing the island like assembly of 
NTs covered with low-porosity oxide layer. 
 
 
 
69 
 
Stronger acid (perchloric acid) was accordingly studied through system #2 for pre-
anodization electrochemical treatment. More underlying NTs were revealed, as shown in Figure 
4.11. NTs morphology was closer to the expected FG3 outcome with relatively thinner tubes 
wall, high vertical alignment and uniformity. However, although oxide layer was found more 
distant apart, it remained persistent with this polishing technique. Also, overall electropolished 
area was found to be about only 20% of the whole substrate surface area. Furthermore, NTs layer 
assembled on electropolished areas was easily detached with minimum stress. Hence, another 
technique had to be explored for sample polishing. 
 
 
Figure 4.11.: FESEM images of as-anodized Ti-17Nb-6Ta samples, post electrochemical polishing using 
system #2. (A) Top view for relatively thin walled NTs close to the morphology produced by FG3 
electrolyte. And it can also be seen to the right, oxide layer deposited on the surface. (B) Side view of 
highly ordered nanotubes assembly, detached from the layer of almost 11 µm in length. 
 
4.1.3.3. Chemical Etching 
 
Pretreatment in chemically etching solution as described in chapter 3, revealed the best 
results among the different explored polishing techniques. The very strong acid (HF) used 
resulted in the most successful solution to remove the oxide layer built on NTs surface without 
the need of external forces either mechanical or electrochemical. As seen in Figure 4.12, it only 
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left randomly distributed debris revealing highly ordered NTs. Among the previously described 
polishing techniques, chemical etching showed the best results. Results obtained from different 
polishing treatments confirmed that substrate preparation and pre-anodization treatment directly 
and greatly influence the final NTs morphology, uniformity and distribution. 
 
 
Figure 4.12.: Top view FESEM image of as anodized Ti-17Nb-6Ta samples, post chemical etching. (A) 
Lower magnification showing the relatively heterogeneous nanoarchitecture along the surface. (B) High 
magnification at area of highly ordered, vertically oriented NTs with morphology and dimensions as 
expected from FG3 electrolyte. (C) and (D) show the randomly distributed debris on as anodized NTs 
surface.   
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4.1.3.4. Unprocessed Ti-17Nb-6Ta Alloy 
 
Based on the previously reported findings, anodization was done for samples with no 
thermal treatment history post preparation. After samples were cold rolled, they were directly 
anodized in attempt to avoid the oxide layer formation without the need of sample polishing. As 
expected, it is clear from Figure 4.13 that anodization using FG3 electrolyte conditions was 
successful to fabricate highly ordered, vertically oriented NTs for Ti-17Nb-6Ta substrate.   
 
Figure 4.13: FESEM images of as-anodized Ti-17Nb-6Ta with no thermal treatment history. (A) Low 
magnification top view of the highly ordered, vertically oriented NTs packs, with dissimilar packs’ 
length, (B) high magnification top view of the ordered NTs showing NTs homogenous structure, (C) and 
(D) side views of NTs detached layers, showing NTs bottom side at lower and higher magnification, 
respectively. 
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They can also be described as closely packed NTs assembled into honey-comb like 
islands separated by grooves. Packed NTs appeared having fused walls at the surface. Side view 
observed from detached layer or variation in packs length, showed highly defined NTs with 
distinct, uniform walls and free from circumferential serration. Tubes diameter is observed to be 
uniform along the length. As observed from bottom view of Figure 4.13 (C) and (D). It can be 
safely called homogeneous NTs (Homo-NTs), and will be the first morphology of 
nanoarchitecture proposed for the intended application. NTs dimensions were found to be of 
average inner diameter 75 ± 5 nm and length of 12 µm. Dissimilar packs’ length of NTs is 
observed in Figure 4.13 (A). It is potentially justified by different etching rates of Ti-17Nb-6Ta 
alloy components by fluoride containing electrolyte reference to elements activity. This structure 
of homogeneous NTs was studied for enhancing drug eluting stents by enhancing material 
biological response and drug loading capacity as will be described in the following sections. 
 
4.1.3.5. Variation in NTs Morphology for Biological Application 
 
Aqueous electrolyte was studied for anodizing Ti-17Nb-6Ta with no thermal treatment 
history. This was an attempt to reproduce heterogeneous structure observed with Ti-45Nb by 
using aqueous electrolyte. Samples were anodized using AD4 electrolyte conditions and imaged 
with FESEM. As seen in Figure 4.14, anodization was successful to produce vertically aligned 
nanotubes, uniformly distributed on samples’ surface. The structure is referred to as 
heterogeneous NTs (Hetero-NTs) since measurement of inner diameter and wall thickness varied 
significantly. Tubes’ diameter ranged from 80 nm up to 190 nm along the same substrate. Wall 
thickness varied within range of 6 nm up to 28 nm. However, the length of NTs layer was found 
to be of average 12 µm. Heterogeneous NTs were fabricated to be studied in comparison with the 
previously described homogeneous NTs for the intended application. With almost similar layer 
length for the two morphology, this variable was excluded from the comparison. Effect of 
surface morphology between Homo- and Hetero- NTs was studied for endothelial tissue 
biological response and system capacity to load therapeutic agents for drug eluting stents. 
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Figure 4.14: Top view FESEM images of as-anodized Ti-17Nb-6Ta sheets using aqueous AD4 
electrolyte. (A) and (B) show the heterogeneous NTs dimensions at low and high magnification, 
respectively. 
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4.2. Structural and compositional Characterization 
 
Composition and crystallinity of the as-fabricated Ti-17Nb-6Ta samples were first 
examined using X-ray diffraction (XRD) and Raman spectroscopy on annealed sample at 450 o 
C. Figure 4.15, evidently confirms the crystallization of the nanotubes in the anatase phase, with 
appearance of peaks corresponding to (101), (103), (004), (112), (200), (105), (211), (213) and 
(220) facets. These peaks are normally indicative of titania NTs anatase phase as reported in 
literature 173–176. However, absence or existence of the other alloy components, i.e. Nb and Ta, 
cannot be confirmed nor denied from these results. It was reported that both Nb and Ta existence 
with titania may not alter greatly nor postpone its phase transformation from amorphous to 
anatase 177–179. Results from Ti-xNb, Ti-xTa- xZr and Ti-xTa annealed samples at 450 o C 
revealed the same peaks’ positions reported with anatase phase of titania NTs. This indicates 
possible overlapping of peaks from the three components 180–182. 
 
 
Figure 4.15: X-ray diffraction pattern of as-fabricated Ti-17Nb-6Ta NTs, annealed at 450 o C for 3 hours. 
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Results from XRD was supported by Raman spectra, as shown in Figure 4.16. It 
indicated the tetragonal vibration mode symmetries associated with anatase, of peaks 
corresponding to Eg, Eg, B1g and A1g modes 
174,175. However, slight shift and broadening of some 
peaks may be indicative of presence of other elements in the crystal 183.  Yet, no distinctive peaks 
were revealed for Nb or Ta for confirmation. Accordingly, this could not be considered accurate 
analysis for surface composition. 
 
Figure 4.16: Raman spectrum of the fabricated Ti-17Nb-6Ta NTs, annealed at 450 o C for 3 hours. 
 
More sensitive and accurate technique was, therefore, needed for confirming or denying 
the formation of mixed oxides on the as anodized surface. The three alloying elements have 
different activities towards etching and evidence was then needed to make sure the three 
elements were retained during anodization and within the NTs. Accordingly, X-ray 
Photoelectron Spectroscopy (XPS) was used, which results in fingerprint elemental analysis. 
XPS is considered a powerful tool for identifying the surface components, chemical composition 
and oxidation degrees. Spectra for as anodized Ti-17Nb-6Ta samples, indicated the presence of 
Ti, Nb, Ta, and O elements, and confirmed the formation of Ti-Nb-Ta mixed oxides, as 
illustrated in Figure 4.17. 
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Figure 4.17: XPS spectra of the (A) Ti 2p, (B) Nb 3d, (C) Ta 4f and (D) O 1s emission peaks for Ti-
17Nb-6Ta as-anodized formed nanotubes. 
 
Figure 4.17 shows the XPS spectra for the alloy. Figure 4.17 (A) shows two peaks that can be 
assigned to Ti 2p1/2 and Ti 2p3/2. The peaks are located at 464.6 eV and 458.7 eV with spin orbit 
splitting (Δ) = 5.9 eV associated with Ti4+ (1). Figure 4.17 (B) revealed Nb3d doublet at 210.98 
eV and 208.08 eV associated with Nb 3d3/2 and Nb 3d5/2. It showed spin orbit splitting (Δ) = 2.9 
eV, confirming that signals correspond to Nb5+ (2). In Figure 4.17 (C), peaks appeared at 29.08 
eV for Ta4f5/2 and 27.18 eV for Ta4f7/2. Spin orbit splitting (Δ) was found to be equal 1.9 eV 
confirming presence of Ta5+. Finally, Figure 4.17 (D) shows Oxygen indicative peak O1s, with 
only single peak is observed located at 530.98 eV.   
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These results were supported by Energy dispersive X-ray spectroscopy (EDX) as a 
qualitative elemental analysis technique. As observed from Figure 4.18, EDX showed that the 
surface formed of NTs were composed of Ti, Nb, Ta and O. Overall composition was found to 
be relatively consistent with the composition of the substrate forming alloy, yet Ta content is 
slightly higher than expected. This, however, confirms that compositions of NTs depend upon 
titanium alloy elemental composition. 
 
Figure 4.18: EDX peaks and composition of Ti-17Nb-6Ta-1O formed nanotubes, analysed within the 
specified spectrum  
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4.3. Nanomechanical Characterization 
 
Not only that material mechanical properties are critical for drug eluting stents, but also 
biological interaction with material surfaces is sensitive to mechanical properties at the interface. 
Surface stiffness was found to significantly influence cells fate 57,184.The mechanical properties 
of the fabricated nanoarchitectures were measured using nanoindentation technique. 
Nanoindentation tip was used to obtain Young’s modulus (a measure of stiffness) and hardness 
values, before and after annealing. During loading and unloading, hysteresis loop was observed, 
which indicated that NTs surface has elastic energy dissipation, as seen in Figure 4.19. It can be 
observed from the curves below, that elastic recovery is higher for annealed sample (Figure 4.19 
(B) and (D)) reference to their unannealed counterpart. Also, unloading slope of annealed 
samples are found to be steeper indicating higher stiffness. 
  
 
 
 
 
 
  
 
 
 
 
 
Figure 4.19: Average load-displacement curves from nanoindentation of (A), (B) Homo-NTs and (C), (D) 
Hetero-NTS, before and after annealing respectively. 
(A) 
(B) 
(C) (D) 
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From inspecting Figure 4.19, total depth of indentation is much smaller than the NTs 
layer thickness (12 µm). Accordingly, insights on NTs plastic deformation behavior can be 
gained without interference from substrate material. Young’s modulus and hardness average 
values were calculated and compared for Homo-NTs and Hetero-NTs before and after annealing, 
as shown in Figure 4.20. It was found that both Young’s modulus and hardness increase with 
annealing for both Homo- and Hetero-NTs, which can be explained by phase transformation 
upon annealing. For hardness, Homo-NTs were found to be superior. For Young’s modulus, 
Homo-NTs showed lower values, which does not indicate inferiority within intended application.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20: Young’s modulus and hardness values for Homo- and Hetero-NTs, before and after 
annealing. 
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4.4. Influence of Nanoarchitecture Surface Morphology on Biological 
Response 
 
4.4.1. Cytotoxicity Measurements 
 
As any biomaterial that will be in contact with biological components, assessment of the 
material’s cytotoxicity is crucial to be considered in biomedical applications. This is a mandatory 
step before considering any in-depth proliferation studies. For Ti-17Nb-6Ta alloy, samples were 
assessed to ensure not only the safety of the alloy material, but also the effect of the used 
electrolytes in nanotubes fabrication on materials biocompatibility.  
As described in chapter 4, MTT assay was used to assess cytotoxicity for 3 samples’ 
surfaces: 1) Ti-17Nb-6Ta sheets as received, 2) with Homo-NTs and 3) Hetero-NTs structures. 
Each sample’s extract were tested through 3 different dilutions, each repeated eight times for 
results reproducibility. According to plate design illustrated in chapter 3, microplate reader 
absorbance results were retrieved as described in Table, 4.1 below. Also readings for blank and 
cell control were recorded for percentage of cells viability calculations. 
 
Table 4.1: Absorbance results of MTT assay for Ti-17Nb-6Ta samples; as received substrate and the two 
different nanotubes morphologies fabricated and reported earlier.  
 
 
 
 Blank 
C. 
control Homo-NTs Hetero-NTs Alloy substrate  
 
1 2 3 4 5 6 7 8 9 10 11 12 
A 0.006 0.421 0.422 0.423 0.42 0.423 0.422 0.423 0.421 0.424 0.423   
B 0.007 0.422 0.424 0.421 0.422 0.424 0.421 0.422 0.42 0.421 0.422   
C 0.004 0.423 0.425 0.425 0.423 0.42 0.424 0.423 0.421 0.423 0.422   
D 0.006 0.424 0.423 0.424 0.421 0.422 0.424 0.422 0.424 0.421 0.423   
E 0.005 0.421 0.42 0.422 0.424 0.423 0.421 0.424 0.424 0.422 0.424   
F 0.006 0.423 0.421 0.423 0.423 0.423 0.421 0.422 0.421 0.422 0.421   
G 0.003 0.421 0.421 0.42 0.422 0.423 0.422 0.423 0.421 0.42 0.421   
H 0.006 0.423 0.424 0.422 0.425 0.421 0.423 0.421 0.421 0.424 0.423   
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From absorbance reported data, percentage of cell viability for different samples’ extract 
were calculated using the following equation and presented in Figure 4.21: 
 
𝑆𝑢𝑟𝑣𝑖𝑣𝑎𝑙 𝑟𝑎𝑡𝑒 % =  
𝐴 𝑠𝑎𝑚𝑝𝑙𝑒−𝐴b
𝐴c−𝐴b
 × 100                                                                                  (4.1) 
 
where Ac is the negative control and Ab is blank. 
 
Figure 4.21. Illustrates the percentage of cells survival rate or cell viability for 1) Ti-
17Nb-6Ta sheets with as anodized Homo-NTs, 2) with Hetero-NTs structures, and 3) as received 
substrate material measured by MTT assay. Data present 3 different dilutions for each sample’s 
extract (0, -1, -2). It can be clearly seen that cells survival rate is about 100% for all samples and 
different dilutions. This indicates almost no cytotoxicity at all for the substrate alloy material 
used. It is also clear that results from NTs fabricated using different electrolytes (FG3 for Homo-
NTs and AD4 for Hetero-NTs) are as promising as the substrate material. This exclude any 
possible cytotoxicity from electrolyte after sample cleaning post anodization. 
These results are highly consistent with the biocompatibility and hemocomatability 
reports in literature for Titanium and Titanium alloys 185,186.Such high degree of biocompatibility 
is attributed to the ability of Ti-based alloys to form a stable oxide layer in most environments. 
Furthermore, the thicker and more stable oxide layer, the better is the material bioactivity. This 
has driven earlier attempts to increase biocompatibility and activity of material surfaces by 
increasing oxide layer through anodization techniques 187-190. 
For Drug eluting stents (DES) application, material stability and cytotoxicity are 
considered crucial. The use of materials with any inflammatory effect can cause local tissue 
sensitization, which can directly affect the healing process as well as the local thrombogenicity. 
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In this work, NTs are proposed as platform for enhancing endothelial tissue regeneration 
as well as to act as drug carriers. Accordingly, it is proposed to replace polymer coating on stents 
struts, which leaves Ti-17Nb-6Ta substrate and NTs in direct contact with biological 
components. This confirms the significance of % cells viability results obtained for the material 
under study. From results reported in Figure 4.21, Ti-17Nb-6Ta can be potential material for 
DES and can be considered for further in-depth investigation regarding proliferation studies. 
 
 
 
Figure 4.21: Mean values of percentage of cell viability for 1) Ti-17Nb-6Ta sheets with Homo-NTs, 2) 
with Hetero-NTs structures and as received substrate. It is illustrated for each sample, values for three 
different dilutions (0, -1, -2) of tested samples extracts. 
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4.4.2. Activation of Endothelial Cells Growth on Ti-based Nanoarchitectures 
  
Ultimate vascular conditions post percutaneous coronary angioplasty and stenting can be 
described as fast controlled healing of endothelial cells. Endothelial cells regeneration at site of 
injury would directly enhance patient prognosis and stenting outcomes. As the inner most lining 
of the blood vessel, intact endothelial cells can prevent thrombus formation as well as avoid 
neointimal hyperplasia. This would allow the need of lower doses of local cytotoxic drugs and 
more importantly would decrease the duration of oral antiplatelet therapy required for the 
patients.  
As reported in chapter 2, nanoarchitectures supported the migration, adhesion and 
proliferation of mesenchymal stem cells and endothelial cells. Different biological response was 
studied and reported for samples of different NTs diameters 109, 139-141. In this work, the influence 
of nanoarchitecture of as anodized Ti-17Nb-6Ta was studied versus smooth substrate surface of 
the same material. Furthermore, the effect of another morphology related factor on cells 
activation was investigated. This factor involved NTs dimensional homogeneity, by comparing 
endothelial cells proliferation on Homo-NTs prepared by FG3 electrolyte conditions versus 
Hetero-NTs prepared by AD4 electrolyte conditions.  
This section reports studies of endothelial cells proliferation for 3 types of Ti-17Nb-6Ta 
samples; 1) Smooth surface of as received alloy, 2) Homo-NTs and 3) Hetero-NTs. Proliferation 
results were reported using 3 different studies: 
- Cell counts from Tryptan blue cells viability assay. 
- MTT cells viability assay using absorbance data as an indicative measure. 
- Visual observation by imaging under FESEM. 
 
4.4.2.1. Trypan Blue Cells Viability Assay 
 
The three different samples underwent tryptan blue viability assay, and for each sample 
both dead and viable cells were counted under the microscope at specific time intervals of 1, 3 
and 7 days. Counted viable cells of the three samples are illustrated and compared below at the 
specified time intervals, as shown in Figure 4.22.  
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It is evident from the graphical representation in Figure 4.22 that nanoarchitectures 
directed better proliferation of endothelial cells than smooth surface of material substrate at the 
three studied time intervals. This directly supports the proposed hypothesis that surface 
modification of drug eluting stents with nanotopography would guide faster endothelial healing. 
Therefore, replacing the DES polymeric coating with NTs can be of great potential towards 
better stenting outcome in terms of biological response. This shall not only spare the local 
inflammation that may be caused by used polymer, but also promote endothelial tissue proper 
healing. 
  Furthermore, the effect of changing surface topographies through differently anodized 
samples were compared. Homo-NTs clearly showed higher number of counted cells than Hetero-
NTS, indicating better proliferation. This signifies the importance of NTs optimization in terms 
of dimensional homogeneity, which should be considered for the applications involving tissue 
regeneration. During endothelialization, nanoarchitectures mimic temporarily extracellular 
matrix (ECM) guiding and nurturing cells growth 113, 191. Superior outcome from Homo-NTs 
may be attributed to better distribution of ions, proteins and nutrients required for the growth, as 
well as more structured spatial guidance of cells to grow. 
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Figure 4.22: Viable endothelial cells count on 1) Ti-17Nb-6Ta smooth surface 2) with Homo-NTs, 3) 
with Hetero-NTs structures at different time intervals (1, 3 and 7 days) 
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4.4.2.2. MTT Assay: 
 
For confirming trypan blue assay results, MTT assay was conducted for the same 3 types 
of samples of Ti-17Nb-6Ta; 1) Smooth surface of as received alloy, 2) Homo-NTs and 3) 
Hetero-NTs. Absorbance of Formazan solutions was reported as a reflection of viable cells 
concentration per sample. Reading were accordingly compared, as shown in Figure 4.23. Better 
outcome with nanoarchitecture was confirmed versus smooth surface. Also, Homo-NTs showed 
the same trend reported with trypan blue assay as the superior morphology for proliferation 
among the three samples. 
 
 
Figure 4.23: Formazan absorbance from MTT cell viability assay for: 1) Ti-17Nb-6Ta smooth surface 2) 
with Homo-NTs, 3) with Hetero-NTs structures at different time intervals (1, 3 and 7 days) 
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4.4.2.3. FESEM Imaging of Cells Proliferation 
 
Endothelial cells were grown on the surface of Homo-NTs and Hetero-NTs for 3 days to 
confirm the effect of dimensional homogeneity on cells’ proliferation. Cells were fixed and 
imaged using FESEM, as shown in Figure 4.24. Cells morphology and degree of proliferation 
shown in Figure 4.24, confirm the superiority of Homo-NTs in guiding endothelialization over 
Hetero-NTs. 
 Images (A),(C) and (E) on the left side of Figure 4.24, represents cells’ growth on 
Homo-NTs, where the island like structure of highly ordered nanotubes can be seen at the 
highest magnification (E). While, images (B), (D) and (F) on the right side of the figure 
illustrates cells on Hetero-NTs, and as well at highest magnification (F) NTs with different 
diameters can be observed. 
Elongated endothelial cells are predominantly seen on Homo-NTs. On the same 
morphology cells are more distributed and almost forming network like structure. Also, cells 
show more pronounced filopodia protrusions. This indicates better cells migration and 
proliferation more on the homogeneous structure of NTs, which would directly results in higher 
cells count as seen in the former assays. Cells cultured on Hetero-NTs, on the other hand, 
showed more rounded structure, less spread on the surface and not yet crossing into a network. 
This indicates potential of slower healing rates for Hetero-NTs in applications.  
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Figure 4.24: Top view FESEM images of endothelial cells grown on NTs surfaces after 3 days. 
(A), (C) and (E) are cells grown on Homo-NTs at different magnification. (B), (D) and (F) are 
cells grown on Hetero-NTs at different magnification. 
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4.5. Ti-based Nanoarchitectures as Drug Reservoir 
 
4.5.1. Drug Loading 
  
Work reported in this section was intended to evaluate the potential use of the fabricated 
nanoarchitectures as drug reservoir. This is a critical feature for any material to be proposed as a 
platform for DES surface modification. As polymer coatings replacement, Ti-based NTs are 
intended to locally deliver any of drug classes used to avoid neointimal hyperplasia. The 
proposed platform is intended to deliver the drug only into the vascular tissue side and not the 
vessel lumen. Accordingly, anodized samples were tested for drug loading only on one side of 
the sheet covered with the NTs layer, to avoid interference or duplication of results from the 
other NTs layer.   
Concentration of loaded drug in 1 cm2 NTs layer was calculated, using the calibration 
curve described in chapter 3. This was done for both Homo-NTs and Hetero-NTs of 12 µm 
length. Amount of loaded drugs were calculated and plotted, as shown in Figure 4.25.  
 
 
Figure 4.25: Comparison between drug loading capacity of Homo-NTs and Hetero-NTs. 
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Results were compared between the two NTs morphologies to assess system superiority. 
It is evident from Figure 4.25 that Homo-NTs drug loading capacity is almost double Hetero-
NTs. This can be explained by grooves found with Homo-NTs between islands of compact 
nanotubes, see Figure 4.26. These grooves can reach width of up to 1 µm. Accordingly, they can 
act as potential reservoir for higher amounts of drug causing this gap between both platforms. As 
described, Homo-NTs showed more promising results for both biological response as well as 
drug loading. Accordingly, it was further studied for its drug release profile using computational 
analysis. 
 
 
 
Figure 4.26: FESEM image, top view of Homo-NTs, showing grooves between compact NTs 
islands 
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4.5.2. Drug Release by Computational Simulation 
 
In this work, a simulated model was used to examine and describe the release profile of 
2’- deoxyadenosine from Homo-NTs. “Transport of diluted species” module was used for the 
simulation. As concluded from previously reported biological response and drug loading for the 
two NTs morphologies, results came in favour of Homo-NTs. Accordingly, release behaviour 
was furthermore predicted for the practically loaded amount of drug from Homo-NTs. In order to 
simulate the system, the physical model was first defined to identify model’s geometry, system 
parameters, boundary’s conditions and equations that would govern the simulation. 
Figure 4.27 facilitates the description of the system’s physical model. The figure shows a 
cross section of the vessel at the healthy state (on the left) and after stenting (on the right). With 
healthy vessels, wall tissue is still intact and demonstrating the three layers building the wall; 1) 
innermost “Intima” (endothelium lining followed by connective tissue), 2) the middle layer 
“Media” (composed of smooth muscles) and 3) The connective tissue of the outer layer 
“Adventitia”. However, after stenting, metal struts are embedded into the intima with direct 
contact with the connective tissue, while endothelium is almost damaged. Stent is taking the 
shape of a ring, spanning the entire vessel circumference. Atherosclerotic plaque is 
hypothetically considered to be totally removed during PTCA. 
By magnifying at stent-tissue interface, the NTs delivery system is illustrated. Homo-NTs 
are grown vertically on Ti-alloy substrate, which is embedded in the vessel wall tissue. Drug 
release is intended to be in the direction of vessel wall only, hence not affected by the central 
blood flow in the vessel lumen. Therefore, mass transport in the model was identified to be 
dominated by diffusion and excluded both convection and migration. Accordingly, equation that 
governed the drug motion was set to be of Fick’s law:  
     
𝜕c𝑖
𝜕t
   = Di . ∇2 ci                                                                                                                                                                         (4.2) 
where for species i, Di = the diffusion coefficient (m2 /s), and ci = the concentration (mol /m3). 
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A) Vascular tissue in direct contact 
with NTs. 
B) NTs fabricated on the surface of 
stent substrate. 
C) Direction of drug elution from 
NTs. 
D) Stent struts (substrate material). 
E) Blood flow inside vessel lumen. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.27: Illustration of physical model representing the NTs drug delivery system into vessel’s tissue. 
The Figure is just diagrammatic representation, not representing actual relative dimensions of the system 
components. 
After Stent deployment Healthy Vessel 
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Drug release was assumed to be restricted to the surrounding tissue moving across the 
connective tissue of Intima layer – as endothelium lining is damaged – and into the Media. 
Boundary conditions were therefore described to restrict the flux within that system and indicate 
that flux outside its boundaries is equal to zero (n. Ni = 0). Accordingly, the model geometry was 
built as shown in Figure 4.28 with 2D spatial dimension, comprising the modeling domains 
within the system boundaries; the NTs, Intima layer (excluded damaged endothelium and Media 
layer. 
 
 
 
Figure 4.28: 2D geometry of the modeling domains for drug release from NTs. 
 
Simulation parameters were identified reference to the previously reported practical 
results. Dimensions of Homo-NTs were about 75 nm in diameter and 12 µm in length, as 
fabricated by FG3 electrolyte conditions. Initial drug concentration in the NTs was 0.001671 
mol/m3, which was loaded within 36 hours in static conditions. Materials of the model domain 
were identified according to their diffusion coefficient (Dc). For Intima, Dc is = 5.4 × 10 
-12 
m2/sec and for Media Dc is = 5.0 × 10 
-14 m2/sec 192. This difference in D can directly affect the 
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drug elution as diffusion coefficient can be the rate limiting step for mass transport across the 
system. Diffusion coefficient of the drug in the NTs was calculated using the following equation 
193: 
√
𝑀𝑡
𝑀𝑜  ×2
 = 
𝐷𝑡
𝜋 ℎ2
                                                                                                         (4.3) 
where Mt is equal to the amount of drug released at time t, Mo is equal to the initial drug amount 
and h is the layer thickness.  
 
These values were retrieved from practical data measured for the same drug by Kang, et 
al 138. Calculated value of drug diffusion coefficient was found to be = 2.5 × 10 -11 m2/sec. Using 
the aforementioned parameters, time dependant study was designed for the drug release profile. 
Concentration distribution of the drug was simulated as a function of time across the NTs and the 
wall tissue (Intima and Media). Figure 4.29 shows drug concentration across the modeling 
domains, using the 2D geometry and its 3D representation by axial symmetry at the end of the 
simulation (3 days). Darkest red area represents the higher drug concentration, while darkest blue 
represents the lower concentrations. 
Time dependant estimation of drug released was used to plot drug concentration in NTs 
over time. As seen in Figure 4.30, almost 100% of the initial drug amount was released after 3 
days. For DES, this rate can be considered faster than required, reference to polymeric coating 
drug release over duration of one month. This may need more control over the system by for 
example any of the strategies mentioned in chapter 2, such as polymeric coatings over NTs 
pores, using drug carriers or external fields 140. 
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Figure 4.29: Drug concentration over the modeling domain with A) 2D and B) 3D geometry at 
the end of simulation (3 days).  
 
(A) 
(B) 
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Figure 4.30: Calculated drug concentration in the NTs over time 
 
However, other factors may have resulted in such relatively fast rate other than the 
inherent properties of the NTs system. This may include the initial amount of loaded drug. It is 
assumed that drug loading may increase by increasing the initially added drug and the techniques 
used for loading other than static solutions. This may not only increase the total amount of drug 
released but also decrease the elution rate. Also, the nature of the drug is a critical factor in such 
context. The tested drug (2’- deoxyadenosine) is hydrophilic with higher diffusion coefficient 
than hydrophobic drugs used mainly in the market. Extending the measurement into hydrophobic 
molecules with lower diffusivity may slow down the rate and sustain the release. 
 
 
97 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5: Conclusions and Future Perspective 
 
 
 
 
 
 
 
98 
 
Chapter 5: Conclusions and Future Perspective 
 
Complications associated with drug eluting stents arise from its vulnerability to in-stent 
thrombosis. This is directly attributed to late regeneration of endothelial cells, lining the blood 
vessels, injured during mechanical perfusion of the vessel. Furthermore, undesired events can be 
associated with potential hypersensitivity of local biological medium to stent polymeric coating. 
In this thesis, a biologically active, and possibly drug bearing system was proposed to replace 
polymeric coating on stent as surface modification. This system comprises self-grown 
nanoarchitectures for Ti-17Nb-6Ta alloy that has potential for use in fabricating self-expandable 
stents.  
Two nanotube (NTs) morphologies were successfully fabricated for the same substrate 
using anodization technique: 1) Homo-NTs, characterized by highly ordered, vertically aligned 
nanotubes of uniform and homogeneous tubes diameter, closely packed into islands separated by 
grooves. 2) Hetero-NTs, characterized by highly ordered, vertically aligned nanotubes but of 
non-uniform and heterogeneous tubes diameter, yet, evenly distributed along the substrate. 
Different morphologies were obtained by using different types of electrolytes and conditions for 
anodization setup. 
XRD and Raman analysis for the as-anodized samples indicated the formation of the 
anatase phase associated with annealed titania NTs. Possible overlapping of peaks from other 
alloying elements (Nb and Ta), hindered accurate compositional analysis using those two 
techniques. Therefore, XPS as more sensitive and highly powerful technique for elemental 
analysis was used. It was able to confirm the formation of mixture oxides of the alloying 
elements on the surface without totally losing one of the components during anodization. 
Elemental analysis was further confirmed with EDX, which showed Ti, Nb, Ta and O with 
overall composition relatively consistent with the composition of the substrate alloy.  
Nanoindentation technique was used to obtain the Young’s modulus and hardness values 
for the fabricated morphologies before and after annealing. It was reported that phase 
transformation occurred with samples annealed resulted in higher values of Young’s modulus 
and hardness for both samples. Comparative observation between the two morphologies revealed 
that Homo-NTs showed the higher hardness, while Hetero-NTs gave higher stiffness values. 
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For influence of the proposed system on endothelial healing, both morphologies (Homo- 
and Hetero-NTs) were investigated in-vitro with cultured vascular endothelial cells. First, 
cytotoxicity study was done to assess the material biocompatibility. By using, MTT assay it was 
found that after incubation of samples’ extracts with cells for 48 hours, concentration of viable 
cells were almost similar to cell control. Both morphologies as well as substrate material showed 
no cytotoxicity and were ready for further biological investigation. For proliferation studies 
Trypan blue cell count and MTT assay were undertaken for samples cultured with cells for 1, 3 
and 7 days. Along the three time intervals, nanoarchitectures showed significantly better results 
for endothelial cells proliferation. Furthermore, Homo-NTs showed superior activity than 
Hetero-NTs for biological response. 
Drug loading capacity was practically investigated and compared for the two 
morphologies using 2’- Deoxyadenosine drug. Results were as well in favor of Homo-NTs, 
which showed higher amount of drug retained from initially added concentration. The drug 
release profile for this system was then simulated and calculated through computational studies 
using COMSOL ® Multiphysics software with transport of diluted species module. Within a 
diffusion controlled physical model, a time dependent study calculated drug concentration 
released from the NTs into the tissue across time. It reported that almost 100% of the practically 
loaded amount would be eluted from the NTs within a duration of 3 days. Although this may be 
considered relatively fast rate for the intended application, it is expected that by increasing 
initially loaded amount, tuning tubes diameter and using hydrophobic drugs, more sustained 
release can be obtained. 
Finally, for future perspectives some complimentary work can be suggested as follow: 
- Further in-depth mechanical investigation of the NTs layer is required to ensure the 
mechanical integrity of the system during PTCA and on the long term within the vessel. 
- Studying surface hydrophilicity, which may directly affect its interaction with blood 
components and thrombus formation.  
- Effect of nanoarchitecture on VSMC proliferation that may influence restenosis. 
- Practical investigation of drug release kinetics to support computational calculations. 
- Investigating drug loading capacities and release profile with higher initial drug 
concentrations and for hydrophobic drugs. 
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